WO2016176338A1 - Small molecule ras ligands - Google Patents
Small molecule ras ligands Download PDFInfo
- Publication number
- WO2016176338A1 WO2016176338A1 PCT/US2016/029582 US2016029582W WO2016176338A1 WO 2016176338 A1 WO2016176338 A1 WO 2016176338A1 US 2016029582 W US2016029582 W US 2016029582W WO 2016176338 A1 WO2016176338 A1 WO 2016176338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- halide
- cancer
- compound
- optionally substituted
- Prior art date
Links
- 150000003384 small molecules Chemical class 0.000 title description 9
- 239000003446 ligand Substances 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 152
- 102000016914 ras Proteins Human genes 0.000 claims abstract description 141
- 108010014186 ras Proteins Proteins 0.000 claims abstract description 75
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 27
- 230000011664 signaling Effects 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 150000004820 halides Chemical class 0.000 claims description 61
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000001931 aliphatic group Chemical group 0.000 claims description 53
- 125000004429 atom Chemical group 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000012039 electrophile Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 15
- 238000009739 binding Methods 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 102000001708 Protein Isoforms Human genes 0.000 claims description 14
- 108010029485 Protein Isoforms Proteins 0.000 claims description 14
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 12
- 231100000590 oncogenic Toxicity 0.000 claims description 11
- 230000002246 oncogenic effect Effects 0.000 claims description 11
- 102100030708 GTPase KRas Human genes 0.000 claims description 10
- 102100039788 GTPase NRas Human genes 0.000 claims description 10
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 10
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 10
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 102100029974 GTPase HRas Human genes 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 5
- 208000018084 Bone neoplasm Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 230000004611 cancer cell death Effects 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 238000010171 animal model Methods 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 2
- 208000008723 Capillary malformation-arteriovenous malformation Diseases 0.000 claims description 2
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 claims description 2
- 206010067380 Costello Syndrome Diseases 0.000 claims description 2
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000006334 Gingival Fibromatosis Diseases 0.000 claims description 2
- 208000030839 Hereditary gingival fibromatosis Diseases 0.000 claims description 2
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 2
- 208000006286 Legius syndrome Diseases 0.000 claims description 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 2
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims description 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 230000002568 urticarial effect Effects 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- -1 p53-Mdm2) (Vassilev) Chemical class 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000000463 material Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000003085 diluting agent Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000012267 brine Substances 0.000 description 10
- 239000013058 crude material Substances 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000004850 protein–protein interaction Effects 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 201000005962 mycosis fungoides Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000000126 in silico method Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- 238000003032 molecular docking Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 238000012746 preparative thin layer chromatography Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 4
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 4
- 108091006109 GTPases Proteins 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 4
- 101150015043 Ralgds gene Proteins 0.000 description 4
- 229940078123 Ras inhibitor Drugs 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000007783 downstream signaling Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- WQTPGHSKQDVCQQ-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]piperazine Chemical compound ClC1=CC=CC(Cl)=C1CN1CCNCC1 WQTPGHSKQDVCQQ-UHFFFAOYSA-N 0.000 description 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100037941 GTP-binding protein Di-Ras1 Human genes 0.000 description 3
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 101000951240 Homo sapiens GTP-binding protein Di-Ras1 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ADZUEEUKBYCSEY-UHFFFAOYSA-N 1h-indole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC=CC2=C1 ADZUEEUKBYCSEY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 235000003276 Apios tuberosa Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100025308 GTPase RhebL1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 101150033538 Rala gene Proteins 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- NOAAMORLQWOAEL-UHFFFAOYSA-N ethoxy-n,n-di(propan-2-yl)phosphonamidous acid Chemical compound CCOP(O)N(C(C)C)C(C)C NOAAMORLQWOAEL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000008172 membrane trafficking Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003340 retarding agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- GMACPPQKLRQSSU-UHFFFAOYSA-N 2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.OCCNCCO GMACPPQKLRQSSU-UHFFFAOYSA-N 0.000 description 1
- VDGWJLCMLXSEPW-UHFFFAOYSA-N 2-(5-nitro-1h-indol-3-yl)acetic acid Chemical compound C1=C([N+]([O-])=O)C=C2C(CC(=O)O)=CNC2=C1 VDGWJLCMLXSEPW-UHFFFAOYSA-N 0.000 description 1
- PDFGFQUSSYSWNI-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1CBr PDFGFQUSSYSWNI-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 1
- WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 1
- LAGDURGUNCQADL-UHFFFAOYSA-N 2-methylpropanoic acid;hydrochloride Chemical compound Cl.CC(C)C(O)=O LAGDURGUNCQADL-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YNHLVALLAURVJF-UHFFFAOYSA-N 4-amino-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(N)(C(O)=O)CC1 YNHLVALLAURVJF-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DJNOLPBNRWXXPS-UHFFFAOYSA-N C=CC(Nc1ccc2[nH]cc(Cc3nc(cc(cc4)N)c4[nH]3)c2c1)=O Chemical compound C=CC(Nc1ccc2[nH]cc(Cc3nc(cc(cc4)N)c4[nH]3)c2c1)=O DJNOLPBNRWXXPS-UHFFFAOYSA-N 0.000 description 1
- IZFFIKBSGOJHGS-UHFFFAOYSA-N CC[n]1c2ccccc2c(-c2cccc(C)c2)c1 Chemical compound CC[n]1c2ccccc2c(-c2cccc(C)c2)c1 IZFFIKBSGOJHGS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 0 Cc1c(*)c(*)c2[n]cc(Cc3nc(ccc(I)c4)c4[n]3)c2c1* Chemical compound Cc1c(*)c(*)c2[n]cc(Cc3nc(ccc(I)c4)c4[n]3)c2c1* 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100037949 GTP-binding protein Di-Ras2 Human genes 0.000 description 1
- 102100027988 GTP-binding protein Rhes Human genes 0.000 description 1
- 102100022871 GTPase ERas Human genes 0.000 description 1
- 101710197172 GTPase ERas Proteins 0.000 description 1
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000951231 Homo sapiens GTP-binding protein Di-Ras2 Proteins 0.000 description 1
- 101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 description 1
- 101000677111 Homo sapiens Ras-like protein family member 10A Proteins 0.000 description 1
- 101000686246 Homo sapiens Ras-related protein R-Ras Proteins 0.000 description 1
- 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- YBYCNCPOBIUXHA-UHFFFAOYSA-N NC1(CCNCC1)C(NCCC[n]1c2ccc(CN3CCN(Cc(c(Cl)ccc4)c4Cl)CC3)cc2c(-c2cc(CNc3ccc4[nH]c(Cc5c[nH]c6ccccc56)nc4c3)ccc2)c1)=O Chemical compound NC1(CCNCC1)C(NCCC[n]1c2ccc(CN3CCN(Cc(c(Cl)ccc4)c4Cl)CC3)cc2c(-c2cc(CNc3ccc4[nH]c(Cc5c[nH]c6ccccc56)nc4c3)ccc2)c1)=O YBYCNCPOBIUXHA-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- FSBXSAIDFCRLGB-UHFFFAOYSA-N Nc1ccc2[nH]c(Cc(c3c4)c[nH]c3ccc4NC(CCl)=O)nc2c1 Chemical compound Nc1ccc2[nH]c(Cc(c3c4)c[nH]c3ccc4NC(CCl)=O)nc2c1 FSBXSAIDFCRLGB-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150093978 RALB gene Proteins 0.000 description 1
- 101150010363 REM2 gene Proteins 0.000 description 1
- 101150115260 RIT2 gene Proteins 0.000 description 1
- 102100021577 Ras-like protein family member 10A Human genes 0.000 description 1
- 102100024683 Ras-related protein R-Ras Human genes 0.000 description 1
- 102100025003 Ras-related protein R-Ras2 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 229940124759 SOS inhibitor Drugs 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HGTDLKXUWVKLQX-UHFFFAOYSA-N [3-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=CC(B(O)O)=C1 HGTDLKXUWVKLQX-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- ZDKRMIJRCHPKLW-UHFFFAOYSA-N benzyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC=CC=C1 ZDKRMIJRCHPKLW-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
- 201000002687 childhood acute myeloid leukemia Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000043600 human HRAS Human genes 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000002898 library design Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 208000016035 malignant germ cell tumor of ovary Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 101150115538 nero gene Proteins 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002888 pairwise sequence alignment Methods 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000012356 rap1 GTP-Binding Proteins Human genes 0.000 description 1
- 108010036805 rap1 GTP-Binding Proteins Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- HGDXNZSIJGGDLD-UHFFFAOYSA-N tert-butyl 2-amino-1H-indole-3-carboxylate Chemical compound C(=O)(OC(C)(C)C)C1=C(NC2=CC=CC=C12)N HGDXNZSIJGGDLD-UHFFFAOYSA-N 0.000 description 1
- IOKGWQZQCNXXLD-UHFFFAOYSA-N tert-butyl n-(3-bromopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCBr IOKGWQZQCNXXLD-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000001089 thermophoresis Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
Definitions
- the present invention provides, inter alia, small molecule RAS inhibitors and compositions containing such compounds. Methods for using such compounds or compositions are also provided.
- a relatively unexplored subset of therapeutic targets encompass proteins capable of eliciting biological events through protein-protein interactions (PPIs) (Hopkins et al.). While some PPIs have proven tractable to impediment by small molecules (e.g. p53-Mdm2) (Vassilev), the majority of PPIs have yet to succumb to small molecule modulation, especially in the context of high-throughput screening of standard chemical libraries (Nero). Typical of this class are the RAS GTPases, a wished target in cancer biology due to their high prevalence and essentiality in some lethal malignancies.
- RAS mutations are the most frequent gain of function oncogenic mutations in human cancer, with the KRAS isoform exhibiting the strongest correlation (Prior et al.). Present in 20-30% of all malignancies, it is found at even higher rates in three of the top four most lethal cancers: pancreatic (90%), colon (45%), and lung (35%) (Downward).
- RAS proteins have proven historically resistant to small molecule inhibition, as active site nucleotide affinity (pM range) precludes competitive inhibition strategies (John et al.). Coupled with a protein topography that fails to present binding regions for effective allosteric modulation, clinical and pre-clinical evaluation of what is considered to be the "holy grail" of cancer targets— RAS inhibitors— has been limited.
- RAS proteins play a critical role in several signal transduction pathways regulating cell growth and differentiation. Functioning as a binary switch, RAS GTPases transition from an inactive GDP-bound conformation to an active GTP- bound form mediated by guanine nucleotide exchange factors (GEFs, namely sons of sevenless, SOS) and GTPase activating proteins (GAPs) (Hall et al.). GTP binding enables a conformational change that permits RAS interaction with its effector proteins. Mutations resulting in the impairment of RAS inactivation contribute towards reinforcing downstream signaling pathways that result in a malignant phenotype.
- GEFs guanine nucleotide exchange factors
- GAPs GTPase activating proteins
- Oncogenic signal transduction is mainly supported by RAS effectors RAF, RALGDS, and PI3K (Downward, Pacold et al., Huang et al., Block et al.) (FIG. 1 ). Targeting these particular PPIs presents an intriguing approach towards mitigating RAS signaling in the context of developing cancer therapeutics.
- the helix targeted a stretch of residues contained within the switch I region of RAS, incorporating a hydrogen-bond surrogate to facilitate plasma stability and cell permeability.
- the relatively underwhelming potency of these compounds impedes further development towards clinical candidates. Although these approaches were potentially valuable in cancers reliant on SOS-mediated activation of wild-type RAS for proliferation, oncogenic RAS would remain largely unaffected through this mechanism.
- Shima et al. examined an in silico approach towards inhibiting surface interaction between RAS and RAF, generating compounds, such as compound 4 (FIG. 2A), with inhibitory constants (Ki) in the 46 to 733 ⁇ range and activity in a colon cancer xenograft model (Shima et al.). Again, the modest potency limits further development, but provides an early example of targeting RAS-specific PPIs. Ostrem et al. more recently developed an approach towards targeting KRAS G12C by exploiting the reactivity of the nucleophilic cysteine residue native to the mutant isoform Ostrem et al.). They used a fragment-based screening strategy to design covalent inhibitors with considerable success.
- FPI Farnesyltransferase inhibitors
- tipifarnib (6) and lonafarnib (7) (See FIG. 2B), progressed to phase II clinical trials, compensatory mechanisms led to disappointing in vivo efficacy, while simultaneous targeting of such mechanisms forfeited any appreciable therapeutic window (Mesa, Ravoet et al.).
- HTS High Throughput Screening
- One embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, which compound selectively binds to a first site on the RAS protein that comprises at least one amino acid near L56.
- Another embodiment of the present invention is a compound having the structure of formula (V): wherein:
- R 4 is selected from a group consisting of no atom, H, aryl, halide, Ci -4 aliphatic, and -0-Ci -4 aliphatic, wherein the Ci -4 aliphatic is optionally substituted with one or more halide;
- R 8 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci -4 alkyl, and combinations thereof;
- R 9 is selected from a group consisting of no atom, H, and aryl optionally substituted with a group consisting of ether, halide, and combinations thereof;
- Ri2, Ri 3, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
- n and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci -4 alkyl or a halide,
- Another embodiment of the present invention is a compound having the structure of formula (VI):
- R 4 is selected from a group consisting of no atom, H, aryl, halide, Ci -4 aliphatic, and -0-Ci -4 aliphatic, wherein the Ci -4 aliphatic is optionally substituted with one or more halide;
- R 8 and R-n are independently selected from a group consisting of no atom, H, alkyi, and aryl, wherein the alkyi is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, d. 4alkyl, and combinations thereof;
- R-io is selected from a group consisting of no atom, H, halide, and Ci -4 aliphatic;
- Ri2, Ri3, Ri4, and Ri 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
- n and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci -4 alkyl or a halide,
- Another embodiment of the present invention is a compound selected from a group consisting of
- Another embodiment of the present invention is a compound having the structure:
- Another embodiment of the present invention is a compound having the structure:
- Another embodiment of the present invention is a compound having the structure:
- Another embodiment of the present invention is a compound having the structure:
- Another embodiment of the present invention is a compound having the structure: wherein R 2 , R13, Ri 4 , and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile,
- Another embodiment of the present invention is a compound selected from a group consisting of
- Another embodiment of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the present invention.
- Another embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a compound of the present invention.
- Another embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of the present invention.
- Another embodiment of the present invention is a method for effecting cancer cell death comprising contacting a cancer cell with an effective amount of a compound of the present invention.
- kits for treating or ameliorating the effects of a disease related to altered RAS signaling in a subject in need thereof comprising an effective amount of a compound or pharmaceutical composition of the present invention packaged together with instructions for its use.
- kits for treating or ameliorating the effects of a cancer in a subject in need thereof comprising an effective amount of a compound or pharmaceutical composition of the present invention, packaged together with instructions for its use.
- Another embodiment of the present invention is a composition comprising a compound of the present invention.
- Another embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, wherein when the compound is bound to the RAS protein, the compound binds to L56 of the RAS protein and blocks the binding of SOS to the RAS protein.
- FIG. 1 is a diagram showing RAS-signaling pathways. RAS downstream signaling through effector proteins PI3K, RAF, and RALGDS promotes cell proliferation.
- FIG. 2 shows chemical structures of previously developed RAS inhibitors targeting (A) effector regions and (B) posttranslational modifications.
- FIG. 3 shows the sites of targeted RAS-effector interactions, regions (A) switch I (red) and switch II (blue) regions (B) D38 (green) and A59 (purple).
- FIG. 4 demonstrates virtual screening efforts targeting the additional shallow pocket adjacent to the trifluoromethylphenyl ring near the L56 site in (A).
- the top-scoring fragment from an in silico screen is shown in (B).
- FIG. 5 shows targeting of the L56 site.
- A depicts the virtual anticipated pose of a fully elaborated 3-site compound docked into 4DSN.
- B shows ligand-receptor interactions at L56.
- FIG. 6 shows the synthesis of the novel 3-site compound 04SBT04 (Scheme 1 ).
- FIG. 7 A and B shows the synthesis of electrophilic fragments to assess covalent inhibiton at L56 site (Scheme 2).
- FIG. 8 shows additional structures involved in the synthesis reactions of Schemes 1 and 2.
- One embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, which compound selectively binds to a first site on the RAS protein that comprises at least one amino acid near L56.
- selectively binds means a binding reaction between two molecules that is at least two times the background and more typically more than 10 to 100 times background molecular associations under physiological conditions.
- compounds "selective" for a given form of a RAS protein may exhibit molecular associations under physiological conditions at least two times the background and more typically more than 10 to 100 times background.
- RAS proteins include all RAS isoforms, which are members of a family of GTPase proteins frequently mutated in numerous cancers.
- RAS isoforms include, but are not limited to HRAS, KRAS, and NRAS.
- the HRAS, KRAS, and NRAS proteins are highly homologous to one another and have similar mechanisms of action. However, these proteins are distinct in their post-translational modifications, resulting in disparate cell trafficking routes and subcellular localization.
- HRAS is the most effective RAS protein at transforming fibroblasts.
- NRAS transforms hematopoietic cells most efficiently.
- KRAS-deficient mice are embryonic lethal whereas NRAS or HRAS knock outs are essentially phenotypically normal (Parikh, et al., 2007).
- sites means any region of a protein, including those regions comprising the exterior, solvent-exposed portion of a protein. Such a site may be a pocket where other protein species or compounds interact with the RAS protein. Sites also may become available for binding upon conformation change. Compounds of the present invention may bind a RAS protein at two or more sites, including 2, 3, 4, 5, 6, 7, 8, 9, 10, or more sites on the RAS protein.
- the compound selectively binds to another site on the RAS protein that comprises at least one amino acid from the switch I region (near D38).
- “near” as it relates to distances from certain residues, such as D38, A59, L56, or 121 , means within about 9 angstroms of the residue, including, but not limited to, within 1 , 2, 3, 4, 5, 6, 7, or 8 angstroms of the residue on the RAS protein that corresponds to the amino acid number (such as 38, 59, 56, or 21 ) of the human HRAS protein.
- the compound selectively binds to another site on the RAS protein that comprises at least one amino acid located between the switch 1 and switch 2 regions (near A59).
- the switch I region located near the D38 site, includes residues 30-40 corresponding to the human RAS protein.
- the D38 site is one region of conserved interaction between RAS proteins and RAF, RALGDS, and PI3K.
- the switch II region is near A59 and comprises residues 60-70 corresponding to the human RAS protein.
- the A59 site is located between the switch I and switch II regions and is adjacent to the D38 site.
- amino acids from any of the regions or locations of a RAS protein disclosed herein include 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids, up to, and including, the number of amino acids comprising the entire designated region or location of RAS.
- the RAS protein is an isoform selected from a group consisting of HRAS, KRAS, NRAS, and combinations thereof.
- the RAS protein is an oncogenic mutant.
- an "oncogenic mutant” is a RAS variant that contains an alteration in the amino acid sequence and has the potential to cause a cell to become cancerous.
- an oncogenic mutant may be a constitutively active, continually GTP-bound isoform of RAS protein.
- the RAS protein is an oncogenic mutant selected from a group consisting of HRAS G12D , KRAS G12D , NRAS Q61 K , NRAS G13V , and NRAS G13D , the mutations based on the human isoform for the respective protein.
- the compound selectively binds to at least one amino acid near L56, D38, and A59 in a RAS protein.
- the compounds of the present invention comprise a region A that binds to at least one amino acid near D38 on a RAS protein and also comprise a heterocycle with at least one ring nitrogen.
- heterocycle means substituted or unsubstituted non aromatic ring structures.
- the heterocycle comprises 3 to 8 membered rings, and at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
- Such heterocycles may include at least one ring nitrogen.
- heterocycle also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic ring(s) can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Heterocycle groups of the present invention include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
- heteroatom as used herein means an atom of any element other than carbon or hydrogen.
- Preferred heteroatoms are nitrogen, oxygen, and sulfur; more preferably, nitrogen and oxygen.
- amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by wherein R 7 , R 8 , and R 8 each independently represent a hydrogen or a hydrocarbyl group, or R 7 and R 8 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
- the term "primary" amine means only one of R 7 and R 8 or one of R 7 , R 8 , and R 8 is a hydrocarbyl group. Secondary amines have two hydrocarbyl groups bound to N. In tertiary amines, all three groups, R 7 , R 8 , and R 8 , are replaced by hydrocarbyl groups.
- C x-y when used in conjunction with a chemical moiety, such as, alkyl, alkenyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain.
- Cx -y alkyl means substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.
- C2- y alkenyl and C2 -y alkynyl refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- aliphatic means a group composed of carbon and hydrogen atoms that does not contain aromatic rings. Accordingly, aliphatic groups include alkyl, alkenyl, alkynyl, and carbocyclyl groups. A preferred Ci -4 aliphatic is a vinyl moiety.
- alkyl means the radical of saturated aliphatic groups that does not have a ring structure, including straight-chain alkyl groups, and branched-chain alkyl groups. In certain embodiments, a straight chain or branched chain alkyl has 4 or fewer carbon atoms in its backbone (e.g., Ci-C 4 for straight chains, C3-C 4 for branched chains).
- alkenyl as used herein, means an aliphatic group containing at least one double bond.
- alkynyl as used herein, means an aliphatic group containing at least one triple bond.
- aryl as used herein includes substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
- the ring is a 3- to 8-membered ring, more preferably a 6-membered ring.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g. , the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
- substituted means moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with the permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g. , which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- halide means a halogen atom such as fluorine, chlorine, bromine, iodine, or astatine.
- an "aromatic ring” is an aryl or a heteroaryl.
- the term “heteroaryl” includes substituted or unsubstituted aromatic single ring structures, preferably 3- to 8-membered rings, more preferably 5- to 7-membered rings, even more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
- heteroaryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g.
- the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
- the A region of the compounds of the present invention comprise a fragment having formula (I):
- ring A is a heterocycle with at least one ring nitrogen
- Ri is selected from a group consisting of no atom, amine, and Ci -4 aliphatic.
- the A region of the compounds of the present invention is selected from a group consisting of:
- the compounds of the present invention comprise a region B that binds to at least one amino acid near A59 on the RAS protein and comprises an indole.
- indole is art-recognized and means any compound containing a benzene ring fused to a pyrrole ring.
- the B region of the compounds of the present invention comprise a structure of formula (III):
- R 3 is selected from a group consisting of heterocycle, aryl, and amine, which heterocycle, aryl, and amine may be optionally substituted with a group selected from halide, Ci -4 aliphatic, and combinations thereof; and
- R 4 is selected from a group consisting of no atom, H, aryl, halide, Ci -4 aliphatic, and -0-Ci -4 aliphatic, wherein the Ci -4 aliphatic is optionally substituted with halide.
- the B region of the compounds of the present invention is selected from a group consisting of
- R 2 and R 5 are independently selected from a group consisting of no atom, aryl, and Ci -4 aliphatic;
- R 4 is selected from a group consisting of no atom, H, aryl, halide, Ci -4 aliphatic, and -0-Ci -4 aliphatic, wherein the Ci -4 aliphatic is optionally substituted with halide.
- the compounds of the present invention comprise a region C, which region comprises a structure of formula (IV):
- R 6 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci -4 alkyl, and combinations thereof.
- ether means a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O- Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O- heterocycle and aryl-O-heterocycle. Ethers include "alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
- the compounds of the present invention comprise a region D that binds to at least one amino acid near L56 on the RAS protein comprising a structure of formula (VII):
- Ri 2 , R13, Ri 4 , and R15 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH, 0, and S, and wherein E is an electrophile.
- electrophile has its ordinary art-recognized meaning.
- Preferred electrophiles according to the present invention include:
- Y is selected from a group consisting of CI, Br, F, I, and N 2 ;
- Z is selected from a group consisting of O and NH
- R-I 6 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with a group consisting of halide, ether, Ci -4 alkyl, and combinations thereof; and
- p 1 , 2, or 3.
- Another embodiment of the present invention is a compound having the structure of formula (V):
- R 4 is selected from a group consisting of no atom, H, aryl, halide, Ci -4 aliphatic, and -0-Ci -4 aliphatic, wherein the Ci -4 aliphatic is optionally substituted with one or more halide;
- R 8 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci -4 alkyl, and combinations thereof;
- R 9 is selected from a group consisting of no atom, H, and aryl optionally substituted with a group consisting of ether, halide, and combinations thereof;
- Ri2, Ri3, Ri4, and Ri 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
- n and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci -4 alkyl or a halide,
- the term "crystalline form" means the crystal structure of a compound.
- a compound may exist in one or more crystalline forms, which may have different structural, physical, pharmacological, or chemical characteristics. Different crystalline forms may be obtained using variations in nucleation, growth kinetics, agglomeration, and breakage. Nucleation results when the phase-transition energy barrier is overcome, thereby allowing a particle to form from a supersaturated solution. Crystal growth is the enlargement of crystal particles caused by deposition of the chemical compound on an existing surface of the crystal. The relative rate of nucleation and growth determine the size distribution of the crystals that are formed.
- the thermodynamic driving force for both nucleation and growth is supersaturation, which is defined as the deviation from thermodynamic equilibrium.
- Agglomeration is the formation of larger particles through two or more particles (e.g. , crystals) sticking together and forming a larger crystalline structure.
- hydrates as used herein, means a solid or a semi-solid form of a chemical compound containing water in a molecular complex. The water is generally in a stoichiometric amount with respect to the chemical compound.
- pharmaceutically acceptable salts refer to derivatives of the compounds disclosed herein wherein the compounds are modified by making acid or base salts thereof.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2,2'- iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, 1 H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1 -(2- hydroxy-ethyl)-pyrrolidine, sodium hydroxide, triethanolamine (2, 2', 2"- nitrilotris(ethanol)), trometh-amine, zinc hydroxide, acetic acid, 2.2-dichloro-acetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzene
- salts can be formed with cations from metals like aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and the like, (also see Pharmaceutical salts, Berge, S.M. et al. , J. Pharm. Sci., (1977), 66, 1 -19).
- the pharmaceutically acceptable salts of the present invention can be synthesized from a compound disclosed herein which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
- Another embodiment of the present invention is a compound having the structure of formula (VI):
- R 4 is selected from a group consisting of no atom, H, aryl, halide, Ci -4 aliphatic, and -0-Ci -4 aliphatic, wherein the Ci -4 aliphatic is optionally substituted with one or more halide;
- R 8 and R-n are independently selected from a group consisting of no atom, H, alkyi, and aryl, wherein the alkyi is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, d. 4alkyl, and combinations thereof;
- R-i o is selected from a group consisting of no atom, H, halide, and Ci -4 aliphatic;
- Ri2, Ri 3, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
- n and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci -4 alkyl or a halide,
- an "integer between 0-5" means 0, 1 , 2, 3, 4, or 5.
- Examples of preferred compounds of the present invention include:
- each compound of the present invention defined by or including a fragment defined by formulae I - VII selectively binds a RAS protein at three or more sites. More preferably such compounds selectively bind to a site on the RAS protein that comprises at least one amino acid near L56, a site on the RAS protein that comprises at least one amino acid from the switch 2 region (near D38), and a site on the RAS protein that comprises at least one amino acid between the switch 1 and switch 2 regions (near A59).
- the compounds of the present invention may selectively bind to 4 or more sites on the RAS protein such as 5, 6, 7, 8, 9, or 10 sites.
- Another embodiment of the present invention is a compound having
- Ri 2 , R13, Ri 4 , and R-15 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile,
- Another embodiment of the present invention is a compound selected from a group consisting of
- Another embodiment of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of the present invention.
- the compounds or compositions, including pharmaceutical compositions, of the present invention may be administered in any desired and effective manner: for oral ingestion, or as an ointment or drop for local administration to the eyes, or for parenteral or other administration in any appropriate manner such as intraperitoneal, subcutaneous, topical, intradermal, inhalation, intrapulmonary, rectal, vaginal, sublingual, intramuscular, intravenous, intraarterial, intrathecal, or intralymphatic. Further, compounds or compositions, including pharmaceutical compositions, of the present invention may be administered in conjunction with other treatments. Compounds or compositions, including pharmaceutical compositions, of the present invention may be encapsulated or otherwise protected against gastric or other secretions, if desired.
- compositions including pharmaceutical compositions, of the invention comprise one or more active ingredients in admixture with one or more pharmaceutically-acceptable diluents or carriers and, optionally, one or more other compounds, drugs, ingredients and/or materials.
- the active agents/compounds of the present invention are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art. See, e.g. , Remington, The Science and Practice of Pharmacy (21 st Edition, Lippincott Williams and Wilkins, Philadelphia, PA.).
- Pharmaceutically acceptable diluents or carriers are well known in the art (see, e.g. , Remington, The Science and Practice of Pharmacy (21 st Edition, Lippincott Williams and Wilkins, Philadelphia, PA.) and The National Formulary (American Pharmaceutical Association, Washington, D.C.)) and include sugars (e.g. , lactose, sucrose, mannitol, and sorbitol), starches, cellulose preparations, calcium phosphates (e.g. , dicalcium phosphate, tricalcium phosphate and calcium hydrogen phosphate), sodium citrate, water, aqueous solutions (e.g.
- saline sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, lactated Ringer's injection
- alcohols e.g. , ethyl alcohol, propyl alcohol, and benzyl alcohol
- polyols e.g. , glycerol, propylene glycol, and polyethylene glycol
- organic esters e.g. , ethyl oleate and tryglycerides
- biodegradable polymers e.g. , polylactide-polyglycolide, poly(orthoesters), and poly(anhydrides)
- elastomeric matrices e.g., liposomes, microspheres, oils (e.g.
- Each pharmaceutically acceptable diluent or carrier used in a pharmaceutical composition of the invention must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject.
- Diluents or carriers suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable diluents or carriers for a chosen dosage form and method of administration can be determined using ordinary skill in the art.
- compositions including pharmaceutical compositions, of the invention may, optionally, contain additional ingredients and/or materials commonly used in pharmaceutical compositions.
- ingredients and materials are well known in the art and include (1 ) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, sucrose and acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glycerol monoste
- compositions, including pharmaceutical compositions, of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, powders, granules, a solution or a suspension in an aqueous or non-aqueous liquid, an oil-in-water or water-in-oil liquid emulsion, an elixir or syrup, a pastille, a bolus, an electuary or a paste.
- These formulations may be prepared by methods known in the art, e.g., by means of conventional pan-coating, mixing, granulation or lyophilization processes.
- Solid dosage forms for oral administration may be prepared, e.g., by mixing the active ingredient(s) with one or more pharmaceutically-acceptable diluents or carriers and, optionally, one or more fillers, extenders, binders, humectants, disintegrating agents, solution retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, and/or coloring agents.
- Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using a suitable excipient.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using a suitable binder, lubricant, inert diluent, preservative, disintegrant, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine.
- the tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein. They may be sterilized by, for example, filtration through a bacteria-retaining filter.
- compositions may also optionally contain opacifying agents and may be of a composition such that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- the active ingredient can also be in microencapsulated form.
- Liquid dosage forms for oral administration include pharmaceutically- acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain suitable inert diluents commonly used in the art.
- the oral compositions may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. Suspensions may contain suspending agents.
- compositions, including pharmaceutical compositions, of the present invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more active ingredient(s) with one or more suitable nonirritating diluents or carriers which are solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating diluents or carriers which are solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- the pharmaceutical compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such pharmaceutically-acceptable diluents or carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, drops and inhalants.
- the active agent(s)/compound(s) may be mixed under sterile conditions with a suitable pharmaceutically-acceptable diluent or carrier.
- the ointments, pastes, creams and gels may contain excipients.
- Powders and sprays may contain excipients and propellants.
- compositions, including pharmaceutical compositions, of the present invention suitable for parenteral administrations may comprise one or more agent(s)/compound(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain suitable antioxidants, buffers, solutes which render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.
- Proper fluidity can be maintained, for example, by the use of coating materials, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain suitable adjuvants, such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption.
- a drug e.g., pharmaceutical formulation
- the rate of absorption of the active agent/drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
- delayed absorption of a parenterally-adm inistered agent/drug may be accomplished by dissolving or suspending the active agent/drug in an oil vehicle.
- injectable depot forms may be made by forming microencapsule matrices of the active ingredient in biodegradable polymers. Depending on the ratio of the active ingredient to polymer, and the nature of the particular polymer employed, the rate of active ingredient release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue. The injectable materials can be sterilized for example, by filtration through a bacterial-retaining filter.
- Any formulation of the invention may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a lyophilized condition requiring only the addition of the sterile liquid diluent or carrier, for example water for injection, immediately prior to use.
- sterile liquid diluent or carrier for example water for injection
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the type described above.
- An additional embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject.
- the method comprises administering to the subject an effective amount of any compound disclosed herein.
- an "effective amount” or a “therapeutically effective amount” of a compound or composition disclosed herein is an amount of such compound or composition that is sufficient to effect beneficial or desired results as described herein when administered to a subject.
- Effective dosage forms, modes of administration, and dosage amounts may be determined empirically, and making such determinations is within the skill of the art. It is understood by those skilled in the art that the dosage amount will vary with the route of administration, the rate of excretion, the duration of the treatment, the identity of any other drugs being administered, the age, size, and species of mammal, e.g., human patient, and like factors well known in the arts of medicine and veterinary medicine.
- a suitable dose of a compound or composition, including pharmaceutical compositions, according to the invention will be that amount of the compound or composition which is the lowest dose effective to produce the desired effect.
- the effective dose of a compound or composition, including pharmaceutical compositions, of the present invention may be administered as two, three, four, five, six or more sub- doses, administered separately at appropriate intervals throughout the day.
- a suitable, non-limiting example of a dosage of any of the compounds or compositions, including pharmaceutical compositions, disclosed herein is from about 1 mg/kg to about 2400 mg/kg per day, such as from about 1 mg/kg to about 1200 mg/kg per day, 75 mg/kg per day to about 300 mg/kg per day, including from about 1 mg/kg to about 100 mg/kg per day.
- compositions include about 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 400 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, 1000 mg/kg, 1 100 mg/kg, 1200 mg/kg, 1300 mg/kg, 1400 mg/kg, 1500 mg/kg, 1600 mg/kg, 1700 mg/kg, 1800 mg/kg, 1900 mg/kg, 2000 mg/kg, 2100 mg/kg, 2200 mg/kg, and 2300 mg/kg per day.
- ameliorate means to decrease the severity of the symptoms of a disease in a subject.
- the terms "treat,” “treating,” “treatment” and grammatical variations thereof mean subjecting an individual subject to a protocol, regimen, process or remedy, in which it is desired to obtain a physiologic response or outcome in that subject, e.g. , a patient.
- the methods and compositions, including pharmaceutical compositions, of the present invention may be used to slow the development of disease symptoms or delay the onset of the disease or condition, or halt the progression of disease development.
- every treated subject may not respond to a particular treatment protocol, regimen, process or remedy, treating does not require that the desired physiologic response or outcome be achieved in each and every subject or subject population, e.g., patient population. Accordingly, a given subject or subject population, e.g., patient population, may fail to respond or respond inadequately to treatment.
- a "subject" is a mammal, preferably, a human.
- categories of mammals within the scope of the present invention include, for example, primates, farm animals, domestic animals, laboratory animals, etc.
- Some examples of agricultural animals include cows, pigs, horses, goats, etc.
- Some examples of domestic animals include dogs, cats, etc.
- Some examples of laboratory animals include primates, rats, mice, rabbits, guinea pigs, etc.
- altered RAS signaling means any deviation in the activity of a RAS protein from that typically observed from wild-type RAS protein in a given tissue.
- Altered RAS signaling may include, for example, increased RAS signaling or decreased RAS signaling.
- Altered RAS signaling may be caused by one or more mutations in the RAS protein, such as the oncogenic mutations disclosed above. For example, certain RAS protein mutations may enable RAS protein to constitutively exist in its GTP-bound conformation, either by discouraging interaction of RAS protein with various GAP proteins or by disabling the GTPase activity of RAS protein.
- a RAS protein includes, but is not limited to any of the members of the RAS subfamily. Non-limiting examples of RAS subfamily members are set forth in Table 1 , below.
- a disease associated with altered RAS signaling may be a cancer, a neurological disorder, a metabolic disorder, an immunological disorder, an inflammatory disorder, and a developmental disorder.
- the disease is autism, rasopathies, neurofibromatosis type 1 , Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, hereditary gingival fibromatosis type 1 , Legius syndrome, Leopard syndrome, diabetic retinopathy, diabetes, hyperinsulinemia, chronic idiopathic urticarial, autoimmune lymphoproliferative syndrome, and capillary malformation-arteriovenous malformation.
- Another embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of the present invention.
- Another embodiment of the present invention is a method for effecting cancer cell death comprising contacting a cancer cell with an effective amount of a compound of the present invention.
- "contacting” means bringing the compound into close proximity to the cancer cell. This may be accomplished using conventional techniques of drug delivery to mammals or in the in vitro situation by, e.g., providing the compound to a culture media in which the cancer cell is located.
- Suitable and preferred compounds are as disclosed herein.
- effecting cancer cell death may be accomplished in cancer cells having various mutational backgrounds as disclosed above.
- the methods of this embodiment may be used to effect cancer cell death by, e.g., killing cancer cells, in cells of the types of cancer disclosed herein.
- the cancer cell is a mammalian cancer cell.
- the mammalian cancer cell is obtained from a mammal selected from a group consisting of humans, primates, farm animals, and domestic animals and laboratory animals. More preferably, the mammalian cancer cell is a human cancer cell.
- cancers include both solid and hemotologic cancers.
- solid cancers include adrenocortical carcinoma, anal cancer, bladder cancer, bone cancer (such as osteosarcoma), brain cancer, breast cancer, carcinoid cancer, carcinoma, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, Ewing family of cancers, extracranial germ cell cancer, eye cancer, gallbladder cancer, gastric cancer, germ cell tumor, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, islet cell carcinoma, kidney cancer, large intestine cancer, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lung cancer, lymphoma, malignant mesothelioma, Merkel cell carcinoma, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma
- hematologic cancers include, but are not limited to, leukemias, such as adult/childhood acute lymphoblastic leukemia, adult/childhood acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia, lymphomas, such as AIDS-related lymphoma, cutaneous T-cell lymphoma, adult/childhood Hodgkin lymphoma, mycosis fungoides, adult/childhood non-Hodgkin lymphoma, primary central nervous system lymphoma, Sezary syndrome, cutaneous T-cell lymphoma, and Waldenstrom macroglobulinemia, as well as other proliferative disorders such as chronic myeloproliferative disorders, Langerhans cell histiocytosis, multiple myeloma/plasma cell neoplasm, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasm
- the cancer is selected from a group consisting of pancreatic cancer, colorectal cancer, lung cancer, skin cancer, urinary bladder cancer, thyroid cancer, hematopoietic cancer, prostate cancer, breast cancer, liver cancer, soft tissue cancer, leukemia and bone cancer.
- the cancer is selected from a group consisting of pancreatic cancer, colorectal cancer, fibrosarcoma, breast cancer, lung cancer, skin cancer, leukemia and bone cancer.
- kits for treating or ameliorating the effects of a disease related to altered RAS signaling in a subject in need thereof comprising an effective amount of a compound or pharmaceutical composition of the present invention packaged together with instructions for its use.
- kits of the present invention may also include suitable storage containers, e.g. , ampules, vials, tubes, etc., for the compounds and compositions of the present invention and other reagents, e.g. , buffers, balanced salt solutions, etc., for use in administering the compounds and compositions to subjects.
- suitable storage containers e.g. , ampules, vials, tubes, etc.
- other reagents e.g. , buffers, balanced salt solutions, etc.
- the compounds and compositions, including pharmaceutical compositions, of the present invention may be present in the kits in any convenient form, such as, e.g. , in a solution or in a powder form.
- the kits may further include a packaging container, optionally having one or more partitions for housing the compounds and pharmaceutical compositions and other optional reagents.
- Another embodiment of the present invention is a composition comprising a compound of the present invention.
- the composition is a research reagent.
- a “research reagent” is any compound or composition used in the execution of investigational activities.
- Another embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, wherein when the compound is bound to the RAS protein, the compound binds to L56 of the RAS protein and blocks the binding of SOS to the RAS protein.
- each intervening number there between with the same degree of precision is explicitly contemplated.
- the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1 , 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6,9, and 7.0 are explicitly contemplated.
- EDIPA diisopropylethyl amine
- EtOAc ethyl acetate
- MeOH methanol
- DCE 1 ,2-dichloroethane
- Na 2 S0 4 sodium sulfate
- NaHC0 3 sodium bicarbonate
- Boc-amino Indole S 1. To a solution of 1 H-indole-5-carbaldehyde (3.5 g, 24 mmol, 1 .0 equiv) in DMF (100 mL) at 0°C, sodium hydride (60% in mineral oil) (1.1 g, 28.8 mmol, 1 .2 equiv) was added in several portions over 5 minutes. The mixture was stirred for 45 minutes at 0°C before the sequential addition of 3-(Boc- amino)propyl bromide (8.00 g, 33.6 mmol, 1.4 equiv) and sodium iodide (3.6 g, 24 mmol, 1 .0 eq).
- the crude material was extracted with EtOAc (3 x 30 mL) and the combined organic extracts were then washed with water (100 mL) and brine (100 mL), dried (Na 2 S0 4 ), filtered, and concentrated.
- the crude material was purified by flash column chromatography (silica gel, hexanes/EtOAc, 1 :1 ) to afford 9 (1.2 g, 53% yield).
- Triethylamine (0.1 1 mL, 0.81 mmol, 3.0 equiv) and sodium iodide (0.120 g, 0.8 mmol, 3.0 equiv) were added sequentially, and the solution was heated at 80°C overnight. Upon completion, the reaction was quenched with saturated aqueous NH 4 CI and extracted with CH2CI2 (3 x 5 mL). The combined organic extracts were then washed with water (20 mL) and brine (20 mL), dried (Na 2 S0 4 ), filtered, and concentrated. The crude material was purified by flash column chromatography (silica gel, 10% MeOH in CH2CI2) to afford 12 (0.140 g, 80% yield).
- Targeting RAS PPIs initially relied upon analysis of the co-crystal structures of HRAS with ⁇ 3 ⁇ (PDB: 1 HE8), with the RAF RAS-binding domain (RBD, PDB: 3KUD), and with RALGDS (PDB: 1 LFD) in order to gain insights regarding conserved effector regions.
- a particularly persistent site of RAS-effector interaction sits along a short stretch of amino acids within the switch I region (red), highlighted in FIG. 3A to display the apparent overlap with the D38 site (green) shown in FIG. 3B.
- KRAS G12D (PDB: 4DSN) structure revealed a shallow pocket directly adjacent to the D38 site in between the switch I and switch II (blue) regions, denoted as the A59 site (purple).
- RAVOET C; Mineur, P.; Robin, V.; Debusscher, L; Bosly, A.; Andre, M.; Housni, H.
- VALENCIA Alfonso, et al. "The ras protein family: evolutionary tree and role of conserved amino acids.” Biochemistry. 1991 , 30(19), 4637-4648.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides compounds that selectively bind a RAS protein at three or more sites, which compounds selectively bind to a first site on the RAS protein that includes at least one amino acid near L56. Pharmaceutical compositions including a pharmaceutically acceptable carrier and a compound of the present invention are also provided. Methods and kits for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject are also provided. Methods, kits and compositions which include such compounds also are provided.
Description
SMALL MOLECULE RAS LIGANDS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Patent Application Serial No. 62/155,352, filed on April 30, 2015 which application is incorporated by reference herein in its entirety.
GOVERNMENT FUNDING
[0002] This invention was made with government support under grant no. 5R01 CA161061 -04 awarded by the National Institutes of Health. The government has certain rights in the invention.
FIELD OF INVENTION
[0003] The present invention provides, inter alia, small molecule RAS inhibitors and compositions containing such compounds. Methods for using such compounds or compositions are also provided.
BACKGROUND OF THE INVENTION
[0004] A relatively unexplored subset of therapeutic targets encompass proteins capable of eliciting biological events through protein-protein interactions (PPIs) (Hopkins et al.). While some PPIs have proven tractable to impediment by small molecules (e.g. p53-Mdm2) (Vassilev), the majority of PPIs have yet to succumb to small molecule modulation, especially in the context of high-throughput screening of standard chemical libraries (Nero). Typical of this class are the RAS GTPases, a coveted target in cancer biology due to their high prevalence and essentiality in some lethal malignancies. RAS mutations are the most frequent gain
of function oncogenic mutations in human cancer, with the KRAS isoform exhibiting the strongest correlation (Prior et al.). Present in 20-30% of all malignancies, it is found at even higher rates in three of the top four most lethal cancers: pancreatic (90%), colon (45%), and lung (35%) (Downward). RAS proteins have proven historically resistant to small molecule inhibition, as active site nucleotide affinity (pM range) precludes competitive inhibition strategies (John et al.). Coupled with a protein topography that fails to present binding regions for effective allosteric modulation, clinical and pre-clinical evaluation of what is considered to be the "holy grail" of cancer targets— RAS inhibitors— has been limited.
[0005] RAS proteins play a critical role in several signal transduction pathways regulating cell growth and differentiation. Functioning as a binary switch, RAS GTPases transition from an inactive GDP-bound conformation to an active GTP- bound form mediated by guanine nucleotide exchange factors (GEFs, namely sons of sevenless, SOS) and GTPase activating proteins (GAPs) (Hall et al.). GTP binding enables a conformational change that permits RAS interaction with its effector proteins. Mutations resulting in the impairment of RAS inactivation contribute towards reinforcing downstream signaling pathways that result in a malignant phenotype. Oncogenic signal transduction is mainly supported by RAS effectors RAF, RALGDS, and PI3K (Downward, Pacold et al., Huang et al., Block et al.) (FIG. 1 ). Targeting these particular PPIs presents an intriguing approach towards mitigating RAS signaling in the context of developing cancer therapeutics.
[0006] It is important to note that not all endeavors towards small molecule inhibition of RAS signaling have been futile. Over the past two years, several groups have generated substrates exhibiting moderate, yet appreciable, RAS inhibition (See, e.g. FIG. 2). Several reports of small molecule RAS-SOS inhibitors were
published in 2012, typically employing fragment-based drug discovery approaches in order to prevent activation of RAS to its GTP-bound form. Maurer et al. and Sun et al. independently pursued NMR-based fragment screens as an initial method towards identifying molecules capable of binding to RAS, such as compounds 1 and 2 (Sun et al., Maurer et al.) (See, e.g. FIG. 2A). The hits typically incorporated indole-based scaffolds, binding in the conserved site of RAS-SOS interaction near L56. The most potent lead compound described by Maurer et al. (Kd = 1 .5 mM) was the only substrate that exhibited activity in vitro, attenuating EGF-stimulated HEK- 293T cell proliferation. Efforts to elaborate these fragments to a more potent inhibitor were unsuccessful. A cell-permeable, synthetic a-helix (compound 3, FIG. 2A), based on the interacting portion of SOS, was developed as a means to interfere with the RAS-SOS interaction (Patgiri et al.). The helix targeted a stretch of residues contained within the switch I region of RAS, incorporating a hydrogen-bond surrogate to facilitate plasma stability and cell permeability. The peptidomimetic bound nucleotide-free RAS with a KD of 28 μΜ and GDP-bound RAS to a lesser extent (158 μΜ), successfully abrogated RAS signaling in EGF-stimulated HeLa cells. The relatively underwhelming potency of these compounds impedes further development towards clinical candidates. Although these approaches were potentially valuable in cancers reliant on SOS-mediated activation of wild-type RAS for proliferation, oncogenic RAS would remain largely unaffected through this mechanism.
[0007] Shima et al. examined an in silico approach towards inhibiting surface interaction between RAS and RAF, generating compounds, such as compound 4 (FIG. 2A), with inhibitory constants (Ki) in the 46 to 733 μΜ range and activity in a colon cancer xenograft model (Shima et al.). Again, the modest potency limits further
development, but provides an early example of targeting RAS-specific PPIs. Ostrem et al. more recently developed an approach towards targeting KRASG12C by exploiting the reactivity of the nucleophilic cysteine residue native to the mutant isoform Ostrem et al.). They used a fragment-based screening strategy to design covalent inhibitors with considerable success. Their most potent inhibitor (compound 5, FIG. 2A) was shown to irreversibly prevent the RAS-RAF interaction selectively at 100 μΜ in a KRASG12C mutant cell line when compared to cells expressing wild-type KRAS. A drawback is the specificity for the KRASG12C mutant, which represents a limited number of malignant RAS isoforms. In vitro assays also revealed promiscuous binding to other protein targets, a potential pitfall of incorporating the reactive electrophilic moiety.
[0008] Aside from binding RAS directly, drug discovery programs have targeted post-translational modifications, such as farnesylation and palmitoylation, as modes of inhibiting RAS signaling. RAS requires post-translational modifications in order to facilitate membrane trafficking where it can induce downstream signaling (Ahearn et al.). Farnesyltransferase inhibitors (FTI) have been developed as ligand biomimetics of farnesyl pyrophosphate (FPP) analogs, as well as peptide mimetics of the RAS hydrophobic tail region necessary for membrane trafficking (terminal CAAX motif) (Baker et al.). While two inhibitors of this class, tipifarnib (6) and lonafarnib (7) (See FIG. 2B), progressed to phase II clinical trials, compensatory mechanisms led to disappointing in vivo efficacy, while simultaneous targeting of such mechanisms forfeited any appreciable therapeutic window (Mesa, Ravoet et al.).
[0009] Following the disappointing outcome of the FTIs, targeting enzymes involved in RAS localization post-prenylation was explored. PDE65 was recently revealed to be a farnesyl-binding chaperone that facilitates the trafficking and
signaling of RAS (Cox et al.). High Throughput Screening (HTS) was performed with biotinylated and farnesylated KRAS4B against His-tagged PDE65 in an attempt to discover molecules that disrupt this interaction. Several hits containing a benzimidazole scaffold were identified and further optimized, generating inhibitors with activity in a mouse xenograft models (deitarasin, 8, FIG. 2B) (Zimmerman et al.). Although these molecules were not pursued further in a clinical setting, this demonstrated HTS as a viable strategy for treating RAS mutated tumors, while circumventing drawbacks of FTI inhibition.
[0010] Overall, the modest progression of RAS inhibitors into human clinical trials reflects an inability to effectively abrogate the multiple facets of RAS signaling. This is likely due to either suboptimal potency or prevailing compensatory mechanisms. Thus, there exists an unmet need for compounds that selectively bind a RAS protein, particularly an oncogenic mutant of a RAS protein. The present invention details an approach capable of enabling the development of small molecules with sub-micromolar RAS affinity, while efficiently mitigating the multitude of downstream signaling pathways by targeting key protein-protein interactions.
SUMMARY OF THE INVENTION
[0011] One embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, which compound selectively binds to a first site on the RAS protein that comprises at least one amino acid near L56.
[0012] Another embodiment of the present invention is a compound having the structure of formula (V):
wherein:
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci-4alkyl, and combinations thereof;
R9 is selected from a group consisting of no atom, H, and aryl optionally substituted with a group consisting of ether, halide, and combinations thereof;
Ri2, Ri 3, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and
ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0013] Another embodiment of the present invention is a compound having the structure of formula (VI):
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 and R-n are independently selected from a group consisting of no atom, H, alkyi, and aryl, wherein the alkyi is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, d. 4alkyl, and combinations thereof;
R-io is selected from a group consisting of no atom, H, halide, and Ci-4 aliphatic;
Ri2, Ri3, Ri4, and Ri5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0014] Another embodiment of the present invention is a compound selected from a group consisting of
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
[0015] Another embodiment of the present invention is a compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0016] Another embodiment of the present invention is a compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0017] Another embodiment of the present invention is a compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0018] Another embodiment of the present invention is a compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0019] Another embodiment of the present invention is a compound having the structure:
wherein R 2, R13, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof,
with the provisio that at least one of R 2, R13, Ri4, and R 5 are not H.
[0020] Another embodiment of the present invention is a compound selected from a group consisting of
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
[0021] Another embodiment of the present invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the present invention.
[0022] Another embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a compound of the present invention.
[0023] Another embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of the present invention.
[0024] Another embodiment of the present invention is a method for effecting cancer cell death comprising contacting a cancer cell with an effective amount of a compound of the present invention.
[0025] Another embodiment of the present invention is a kit for treating or ameliorating the effects of a disease related to altered RAS signaling in a subject in need thereof, the kit comprising an effective amount of a compound or pharmaceutical composition of the present invention packaged together with instructions for its use.
[0026] Another embodiment of the present invention is a kit for treating or ameliorating the effects of a cancer in a subject in need thereof, the kit comprising an effective amount of a compound or pharmaceutical composition of the present invention, packaged together with instructions for its use.
[0027] Another embodiment of the present invention is a composition comprising a compound of the present invention.
[0028] Another embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, wherein when the compound is bound to the RAS protein, the compound binds to L56 of the RAS protein and blocks the binding of SOS to the RAS protein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0029] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0030] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0031] FIG. 1 is a diagram showing RAS-signaling pathways. RAS downstream signaling through effector proteins PI3K, RAF, and RALGDS promotes cell proliferation.
[0032] FIG. 2 shows chemical structures of previously developed RAS inhibitors targeting (A) effector regions and (B) posttranslational modifications.
[0033] FIG. 3 shows the sites of targeted RAS-effector interactions, regions (A) switch I (red) and switch II (blue) regions (B) D38 (green) and A59 (purple).
[0034] FIG. 4 demonstrates virtual screening efforts targeting the additional shallow pocket adjacent to the trifluoromethylphenyl ring near the L56 site in (A). The top-scoring fragment from an in silico screen is shown in (B).
[0035] FIG. 5 shows targeting of the L56 site. (A) depicts the virtual anticipated pose of a fully elaborated 3-site compound docked into 4DSN. (B) shows ligand-receptor interactions at L56.
[0036] FIG. 6 shows the synthesis of the novel 3-site compound 04SBT04 (Scheme 1 ).
[0037] FIG. 7 A and B shows the synthesis of electrophilic fragments to assess covalent inhibiton at L56 site (Scheme 2).
[0038] FIG. 8 shows additional structures involved in the synthesis reactions of Schemes 1 and 2.
DETAILED DESCRIPTION OF THE INVENTION
[0039] One embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, which compound selectively binds to a first site on the RAS protein that comprises at least one amino acid near L56.
[0040] As used herein, "selectively binds", and grammatical variations thereof, means a binding reaction between two molecules that is at least two times the background and more typically more than 10 to 100 times background molecular associations under physiological conditions. Likewise, compounds "selective" for a given form of a RAS protein may exhibit molecular associations under physiological conditions at least two times the background and more typically more than 10 to 100 times background.
[0041] As used herein, "RAS proteins" include all RAS isoforms, which are members of a family of GTPase proteins frequently mutated in numerous cancers. The terms, "isoform" and grammatical variations thereof, refer to functionally similar proteins that have a similar, but not identical amino acid sequence, and may also be differentially post-translationally modified. RAS isoforms include, but are not limited to HRAS, KRAS, and NRAS. The HRAS, KRAS, and NRAS proteins are highly homologous to one another and have similar mechanisms of action. However, these proteins are distinct in their post-translational modifications, resulting in disparate cell trafficking routes and subcellular localization. Hence, HRAS, KRAS, and NRAS affect cellular processes in distinct ways. For example, HRAS is the most effective RAS protein at transforming fibroblasts. Furthermore, NRAS transforms hematopoietic cells most efficiently. Likewise, KRAS-deficient mice are embryonic lethal whereas NRAS or HRAS knock outs are essentially phenotypically normal (Parikh, et al., 2007).
[0042] The term "sites", and grammatical variations thereof, means any region of a protein, including those regions comprising the exterior, solvent-exposed portion of a protein. Such a site may be a pocket where other protein species or compounds interact with the RAS protein. Sites also may become available for binding upon
conformation change. Compounds of the present invention may bind a RAS protein at two or more sites, including 2, 3, 4, 5, 6, 7, 8, 9, 10, or more sites on the RAS protein.
[0043] In one aspect of this embodiment, the compound selectively binds to another site on the RAS protein that comprises at least one amino acid from the switch I region (near D38). As used herein, "near", as it relates to distances from certain residues, such as D38, A59, L56, or 121 , means within about 9 angstroms of the residue, including, but not limited to, within 1 , 2, 3, 4, 5, 6, 7, or 8 angstroms of the residue on the RAS protein that corresponds to the amino acid number (such as 38, 59, 56, or 21 ) of the human HRAS protein. The corresponding regions of HRAS from other animal, as well as NRAS, KRAS, or other RAS proteins from human and other animals, are also within the scope of the present invention and are readily determined by one skilled in the art. See, e.g., Valencia et al., 1991 . "Corresponds," with reference to amino acid numbers on RAS, means consistent with, as done by sequence alignment. Multiple sequence alignment methods including pair-wise sequence alignment methods, may be used to determine the position in a RAS protein that corresponds to the positions listed above. Methods of sequence alignment are well-known. Many sequence alignment software programs are available. These programs include, e.g., BLAST, ClustalW, SEQALN, DNA Baser, MEME/MAST, BLOCKS, and eMOTIF. Preferably, the sequence alignment software is BLAST.
[0044] In some embodiments, the compound selectively binds to another site on the RAS protein that comprises at least one amino acid located between the switch 1 and switch 2 regions (near A59).
[0045] In the present invention, the switch I region, located near the D38 site, includes residues 30-40 corresponding to the human RAS protein. The D38 site is one region of conserved interaction between RAS proteins and RAF, RALGDS, and PI3K. The switch II region is near A59 and comprises residues 60-70 corresponding to the human RAS protein. The A59 site is located between the switch I and switch II regions and is adjacent to the D38 site.
[0046] As used herein, "at least one amino acid" from any of the regions or locations of a RAS protein disclosed herein include 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids, up to, and including, the number of amino acids comprising the entire designated region or location of RAS.
[0047] In a further aspect of this embodiment, the RAS protein is an isoform selected from a group consisting of HRAS, KRAS, NRAS, and combinations thereof.
[0048] In an additional aspect of this embodiment, the RAS protein is an oncogenic mutant. As used herein, an "oncogenic mutant" is a RAS variant that contains an alteration in the amino acid sequence and has the potential to cause a cell to become cancerous. In the context of a RAS protein, an oncogenic mutant may be a constitutively active, continually GTP-bound isoform of RAS protein. Preferably, the RAS protein is an oncogenic mutant selected from a group consisting of HRASG12D, KRASG12D, NRASQ61 K, NRASG13V, and NRASG13D, the mutations based on the human isoform for the respective protein. In terms of oncogenicity, mutations at residues 12-13 of a RAS protein render RAS's GTPase portion insensitive to activation by GAPs, while mutations at residue 61 affect the enzymatic active site of a RAS protein directly, thereby essentially inactivating the GTPase activity of a RAS protein.
[0049] In another aspect of this embodiment, the compound selectively binds to at least one amino acid near L56, D38, and A59 in a RAS protein. Preferably, the compounds of the present invention comprise a region A that binds to at least one amino acid near D38 on a RAS protein and also comprise a heterocycle with at least one ring nitrogen.
[0050] As used herein, the term "heterocycle" means substituted or unsubstituted non aromatic ring structures. Preferably the heterocycle comprises 3 to 8 membered rings, and at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. Such heterocycles may include at least one ring nitrogen. The term "heterocycle" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic ring(s) can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heterocycle groups of the present invention include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
[0051] The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur; more preferably, nitrogen and oxygen.
[0052] The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
wherein R7, R8, and R8 each independently represent a hydrogen or a hydrocarbyl group, or R7 and R8 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure. The term "primary" amine means only one of R7 and R8 or one of R7, R8, and R8 is a hydrocarbyl group. Secondary amines have two hydrocarbyl groups bound to N. In tertiary amines, all three groups, R7, R8, and R8 , are replaced by hydrocarbyl groups.
[0053] The term "Cx-y" when used in conjunction with a chemical moiety, such as, alkyl, alkenyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. For example, the term "Cx-yalkyl" means substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc. The terms "C2- yalkenyl" and "C2-yalkynyl" refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
[0054] The term "aliphatic", as used herein, means a group composed of carbon and hydrogen atoms that does not contain aromatic rings. Accordingly, aliphatic groups include alkyl, alkenyl, alkynyl, and carbocyclyl groups. A preferred Ci-4 aliphatic is a vinyl moiety.
[0055] The term "alkyl" means the radical of saturated aliphatic groups that does not have a ring structure, including straight-chain alkyl groups, and branched-chain alkyl groups. In certain embodiments, a straight chain or branched chain alkyl has 4 or fewer carbon atoms in its backbone (e.g., Ci-C4 for straight chains, C3-C4 for branched chains).
[0056] The term "alkenyl", as used herein, means an aliphatic group containing at least one double bond.
[0057] The term "alkynyl", as used herein, means an aliphatic group containing at least one triple bond.
[0058] The term "aryl" as used herein includes substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 3- to 8-membered ring, more preferably a 6-membered ring. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g. , the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
[0059] The term "substituted" means moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with the permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g. , which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. The permissible substituents can be one or more and the same or different for appropriate organic compounds.
[0060] As used herein, a "halide" means a halogen atom such as fluorine, chlorine, bromine, iodine, or astatine.
[0061] As used herein, an "aromatic ring" is an aryl or a heteroaryl. The term "heteroaryl" includes substituted or unsubstituted aromatic single ring structures, preferably 3- to 8-membered rings, more preferably 5- to 7-membered rings, even
more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The term "heteroaryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g. , the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
[0062] In a preferred embodiment, the A region of the compounds of the present invention comprise a fragment having formula (I):
wherein ring A is a heterocycle with at least one ring nitrogen, and Ri is selected from a group consisting of no atom, amine, and Ci-4 aliphatic.
[0063] In another preferred embodiment, the A region of the compounds of the present invention is selected from a group consisting of:
[0064] In another preferred embodiment, the compounds of the present invention comprise a region B that binds to at least one amino acid near A59 on the RAS protein and comprises an indole. The term "indole" is art-recognized and means any compound containing a benzene ring fused to a pyrrole ring.
[0065] In a preferred aspect of this embodiment the B region of the compounds of the present invention comprise a structure of formula (III):
wherein
R3 is selected from a group consisting of heterocycle, aryl, and amine, which heterocycle, aryl, and amine may be optionally substituted with a group selected from halide, Ci-4 aliphatic, and combinations thereof; and
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with halide.
[0066] In a preferred aspect of this embodiment the B region of the compounds of the present invention is selected from a group consisting of
wherein
R2 and R5 are independently selected from a group consisting of no atom, aryl, and Ci-4 aliphatic; and
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with halide.
[0067] In another embodiment of the present invention the compounds of the present invention comprise a region C, which region comprises a structure of formula (IV):
(IV)
wherein R6 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci-4alkyl, and combinations thereof.
[0068] The term "ether", as used herein, means a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O- Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O- heterocycle and aryl-O-heterocycle. Ethers include "alkoxyalkyl" groups, which may be represented by the general formula alkyl-O-alkyl.
[0069] In another embodiment of the present invention the compounds of the present invention comprise a region D that binds to at least one amino acid near L56 on the RAS protein comprising a structure of formula (VII):
wherein Ri2, R13, Ri4, and R15 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH, 0, and S, and wherein E is an electrophile.
[0070] In the present invention, "electrophile" has its ordinary art-recognized meaning. Preferred electrophiles according to the present invention include:
wherein:
Y is selected from a group consisting of CI, Br, F, I, and N2;
Z is selected from a group consisting of O and NH; and
R-I 6 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide,
ether, and combinations thereof, and the aryl is optionally substituted with a group consisting of halide, ether, Ci-4alkyl, and combinations thereof; and
p is 1 , 2, or 3.
[0071] Another embodiment of the present invention is a compound having the structure of formula (V):
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci-4alkyl, and combinations thereof;
R9 is selected from a group consisting of no atom, H, and aryl optionally substituted with a group consisting of ether, halide, and combinations thereof;
Ri2, Ri3, Ri4, and Ri5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0072] In the present invention, the term "crystalline form" means the crystal structure of a compound. A compound may exist in one or more crystalline forms, which may have different structural, physical, pharmacological, or chemical characteristics. Different crystalline forms may be obtained using variations in nucleation, growth kinetics, agglomeration, and breakage. Nucleation results when the phase-transition energy barrier is overcome, thereby allowing a particle to form from a supersaturated solution. Crystal growth is the enlargement of crystal particles caused by deposition of the chemical compound on an existing surface of the crystal. The relative rate of nucleation and growth determine the size distribution of the crystals that are formed. The thermodynamic driving force for both nucleation and growth is supersaturation, which is defined as the deviation from thermodynamic equilibrium. Agglomeration is the formation of larger particles through two or more particles (e.g. , crystals) sticking together and forming a larger crystalline structure.
[0073] The term "hydrates", as used herein, means a solid or a semi-solid form of a chemical compound containing water in a molecular complex. The water is generally in a stoichiometric amount with respect to the chemical compound.
[0074] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the compounds disclosed herein wherein the compounds are modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2,2'- iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, 1 H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1 -(2- hydroxy-ethyl)-pyrrolidine, sodium hydroxide, triethanolamine (2, 2', 2"- nitrilotris(ethanol)), trometh-amine, zinc hydroxide, acetic acid, 2.2-dichloro-acetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 2,5-dihydroxybenzoic acid, 4-acetamido-benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, decanoic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, ethylenediamonotetraacetic acid, formic acid, fumaric acid, galacaric acid, gentisic acid, D-glucoheptonic acid, D-gluconic acid, D- glucuronic acid, glutamic acid, glutantic acid, glutaric acid, 2-oxo-glutaric acid, glycero-phosphoric acid, glycine, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid isobutyric acid, DL-lactic acid, lactobionic acid, lauric acid, lysine, maleic acid, (-)-L-malic acid, malonic acid, DL-mandelic acid,
methanesulfonic acid, galactaric acid, naphthalene-1 ,5-disulfonic acid, naphthalene- 2-sulfonic acid, 1 -hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, octanoic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid (embonic acid), phosphoric acid, propionic acid, (-)-L-pyroglutamic acid, salicylic acid, 4-amino- salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)- L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid. Further pharmaceutically acceptable salts can be formed with cations from metals like aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and the like, (also see Pharmaceutical salts, Berge, S.M. et al. , J. Pharm. Sci., (1977), 66, 1 -19).
[0075] The pharmaceutically acceptable salts of the present invention can be synthesized from a compound disclosed herein which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
[0076] Another embodiment of the present invention is a compound having the structure of formula (VI):
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 and R-n are independently selected from a group consisting of no atom, H, alkyi, and aryl, wherein the alkyi is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, d. 4alkyl, and combinations thereof;
R-i o is selected from a group consisting of no atom, H, halide, and Ci-4 aliphatic;
Ri2, Ri 3, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and
ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
[0077] As used herein, an "integer between 0-5" means 0, 1 , 2, 3, 4, or 5.
[0078] Examples of preferred compounds of the present invention include:
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
[0079] Preferably, each compound of the present invention defined by or including a fragment defined by formulae I - VII selectively binds a RAS protein at three or more sites. More preferably such compounds selectively bind to a site on the RAS protein that comprises at least one amino acid near L56, a site on the RAS protein that comprises at least one amino acid from the switch 2 region (near D38), and a site on the RAS protein that comprises at least one amino acid between the switch 1 and switch 2 regions (near A59). The compounds of the present invention
may selectively bind to 4 or more sites on the RAS protein such as 5, 6, 7, 8, 9, or 10 sites.
[0080] Another embodiment of the present invention is a compound having
the structure:
wherein Ri2, R13, Ri4, and R-15 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof,
with the provisio that at least one of R-12, R13, Ri4, and R-1 5 are not H.
[0081] Another embodiment of the present invention is a compound selected from a group consisting of
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
[0082] Another embodiment of the present invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of the present invention.
[0083] The compounds or compositions, including pharmaceutical compositions, of the present invention may be administered in any desired and effective manner: for oral ingestion, or as an ointment or drop for local administration to the eyes, or for parenteral or other administration in any appropriate manner such as intraperitoneal, subcutaneous, topical, intradermal, inhalation, intrapulmonary, rectal, vaginal, sublingual, intramuscular, intravenous, intraarterial, intrathecal, or intralymphatic. Further, compounds or compositions, including pharmaceutical compositions, of the present invention may be administered in conjunction with other treatments. Compounds or compositions, including pharmaceutical compositions, of
the present invention may be encapsulated or otherwise protected against gastric or other secretions, if desired.
[0084] The compositions, including pharmaceutical compositions, of the invention comprise one or more active ingredients in admixture with one or more pharmaceutically-acceptable diluents or carriers and, optionally, one or more other compounds, drugs, ingredients and/or materials. Regardless of the route of administration selected, the active agents/compounds of the present invention are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art. See, e.g. , Remington, The Science and Practice of Pharmacy (21 st Edition, Lippincott Williams and Wilkins, Philadelphia, PA.).
[0085] Pharmaceutically acceptable diluents or carriers are well known in the art (see, e.g. , Remington, The Science and Practice of Pharmacy (21 st Edition, Lippincott Williams and Wilkins, Philadelphia, PA.) and The National Formulary (American Pharmaceutical Association, Washington, D.C.)) and include sugars (e.g. , lactose, sucrose, mannitol, and sorbitol), starches, cellulose preparations, calcium phosphates (e.g. , dicalcium phosphate, tricalcium phosphate and calcium hydrogen phosphate), sodium citrate, water, aqueous solutions (e.g. , saline, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, lactated Ringer's injection), alcohols (e.g. , ethyl alcohol, propyl alcohol, and benzyl alcohol), polyols (e.g. , glycerol, propylene glycol, and polyethylene glycol), organic esters (e.g. , ethyl oleate and tryglycerides), biodegradable polymers (e.g. , polylactide-polyglycolide, poly(orthoesters), and poly(anhydrides)), elastomeric matrices, liposomes, microspheres, oils (e.g. , corn, germ, olive, castor, sesame, cottonseed, and groundnut), cocoa butter, waxes (e.g. , suppository waxes), paraffins, silicones, talc, silicylate, etc. Each pharmaceutically acceptable diluent or
carrier used in a pharmaceutical composition of the invention must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Diluents or carriers suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable diluents or carriers for a chosen dosage form and method of administration can be determined using ordinary skill in the art.
[0086] The compositions, including pharmaceutical compositions, of the invention may, optionally, contain additional ingredients and/or materials commonly used in pharmaceutical compositions. These ingredients and materials are well known in the art and include (1 ) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, sucrose and acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, and sodium lauryl sulfate; (10) suspending agents, such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth; (1 1 ) buffering agents; (12) excipients, such as lactose, milk sugars, polyethylene glycols, animal and vegetable fats, oils, waxes, paraffins, cocoa butter, starches, tragacanth, cellulose derivatives, polyethylene
glycol, silicones, bentonites, silicic acid, talc, salicylate, zinc oxide, aluminum hydroxide, calcium silicates, and polyamide powder; (13) inert diluents, such as water or other solvents; (14) preservatives; (15) surface-active agents; (16) dispersing agents; (17) control-release or absorption-delaying agents, such as hydroxypropylmethyl cellulose, other polymer matrices, biodegradable polymers, liposomes, microspheres, aluminum monostearate, gelatin, and waxes; (18) opacifying agents; (19) adjuvants; (20) wetting agents; (21 ) emulsifying and suspending agents; (22), solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan; (23) propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane; (24) antioxidants; (25) agents which render the formulation isotonic with the blood of the intended recipient, such as sugars and sodium chloride; (26) thickening agents; (27) coating materials, such as lecithin; and (28) sweetening, flavoring, coloring, perfuming and preservative agents. Each such ingredient or material must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Ingredients and materials suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable ingredients and materials for a chosen dosage form and method of administration may be determined using ordinary skill in the art.
[0087] The compositions, including pharmaceutical compositions, of the present invention suitable for oral administration may be in the form of capsules,
cachets, pills, tablets, powders, granules, a solution or a suspension in an aqueous or non-aqueous liquid, an oil-in-water or water-in-oil liquid emulsion, an elixir or syrup, a pastille, a bolus, an electuary or a paste. These formulations may be prepared by methods known in the art, e.g., by means of conventional pan-coating, mixing, granulation or lyophilization processes.
[0088] Solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like) may be prepared, e.g., by mixing the active ingredient(s) with one or more pharmaceutically-acceptable diluents or carriers and, optionally, one or more fillers, extenders, binders, humectants, disintegrating agents, solution retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, and/or coloring agents. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using a suitable excipient. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using a suitable binder, lubricant, inert diluent, preservative, disintegrant, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine. The tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein. They may be sterilized by, for example, filtration through a bacteria-retaining filter. These compositions may also optionally contain opacifying agents and may be of a composition such that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. The active ingredient can also be in microencapsulated form.
[0089] Liquid dosage forms for oral administration include pharmaceutically- acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. The liquid dosage forms may contain suitable inert diluents commonly used in the art. Besides inert diluents, the oral compositions may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. Suspensions may contain suspending agents.
[0090] The compositions, including pharmaceutical compositions, of the present invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more active ingredient(s) with one or more suitable nonirritating diluents or carriers which are solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound. The pharmaceutical compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such pharmaceutically-acceptable diluents or carriers as are known in the art to be appropriate.
[0091] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, drops and inhalants. The active agent(s)/compound(s) may be mixed under sterile conditions with a suitable pharmaceutically-acceptable diluent or carrier. The ointments, pastes, creams and gels may contain excipients. Powders and sprays may contain excipients and propellants.
[0092] The compositions, including pharmaceutical compositions, of the present invention suitable for parenteral administrations may comprise one or more agent(s)/compound(s) in combination with one or more pharmaceutically-acceptable
sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain suitable antioxidants, buffers, solutes which render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents. Proper fluidity can be maintained, for example, by the use of coating materials, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These pharmaceutical compositions may also contain suitable adjuvants, such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption.
[0093] In some cases, in order to prolong the effect of a drug (e.g., pharmaceutical formulation), it is desirable to slow its absorption from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility.
[0094] The rate of absorption of the active agent/drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-adm inistered agent/drug may be accomplished by dissolving or suspending the active agent/drug in an oil vehicle. Injectable depot forms may be made by forming microencapsule matrices of the active ingredient in biodegradable polymers. Depending on the ratio of the active ingredient to polymer, and the nature of the particular polymer employed, the rate of active ingredient release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are
compatible with body tissue. The injectable materials can be sterilized for example, by filtration through a bacterial-retaining filter.
[0095] Any formulation of the invention may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a lyophilized condition requiring only the addition of the sterile liquid diluent or carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the type described above.
[0096] An additional embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject. The method comprises administering to the subject an effective amount of any compound disclosed herein.
[0097] In the present invention, an "effective amount" or a "therapeutically effective amount" of a compound or composition disclosed herein is an amount of such compound or composition that is sufficient to effect beneficial or desired results as described herein when administered to a subject. Effective dosage forms, modes of administration, and dosage amounts may be determined empirically, and making such determinations is within the skill of the art. It is understood by those skilled in the art that the dosage amount will vary with the route of administration, the rate of excretion, the duration of the treatment, the identity of any other drugs being administered, the age, size, and species of mammal, e.g., human patient, and like factors well known in the arts of medicine and veterinary medicine. In general, a suitable dose of a compound or composition, including pharmaceutical compositions, according to the invention will be that amount of the compound or composition which is the lowest dose effective to produce the desired effect. The effective dose
of a compound or composition, including pharmaceutical compositions, of the present invention may be administered as two, three, four, five, six or more sub- doses, administered separately at appropriate intervals throughout the day.
[0098] A suitable, non-limiting example of a dosage of any of the compounds or compositions, including pharmaceutical compositions, disclosed herein is from about 1 mg/kg to about 2400 mg/kg per day, such as from about 1 mg/kg to about 1200 mg/kg per day, 75 mg/kg per day to about 300 mg/kg per day, including from about 1 mg/kg to about 100 mg/kg per day. Other representative dosages of such agents include about 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 400 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, 1000 mg/kg, 1 100 mg/kg, 1200 mg/kg, 1300 mg/kg, 1400 mg/kg, 1500 mg/kg, 1600 mg/kg, 1700 mg/kg, 1800 mg/kg, 1900 mg/kg, 2000 mg/kg, 2100 mg/kg, 2200 mg/kg, and 2300 mg/kg per day. The effective dose of compounds or compositions, including pharmaceutical compositions, disclosed herein, may be administered as two, three, four, five, six or more sub-doses, administered separately at appropriate intervals throughout the day.
[0099] As used herein, the terms "ameliorate", "ameliorating" and grammatical variations thereof mean to decrease the severity of the symptoms of a disease in a subject.
[0100] As used herein, the terms "treat," "treating," "treatment" and grammatical variations thereof mean subjecting an individual subject to a protocol, regimen, process or remedy, in which it is desired to obtain a physiologic response or outcome in that subject, e.g. , a patient. In particular, the methods and
compositions, including pharmaceutical compositions, of the present invention may be used to slow the development of disease symptoms or delay the onset of the disease or condition, or halt the progression of disease development. However, because every treated subject may not respond to a particular treatment protocol, regimen, process or remedy, treating does not require that the desired physiologic response or outcome be achieved in each and every subject or subject population, e.g., patient population. Accordingly, a given subject or subject population, e.g., patient population, may fail to respond or respond inadequately to treatment.
[0101] As used herein, a "subject" is a mammal, preferably, a human. In addition to humans, categories of mammals within the scope of the present invention include, for example, primates, farm animals, domestic animals, laboratory animals, etc. Some examples of agricultural animals include cows, pigs, horses, goats, etc. Some examples of domestic animals include dogs, cats, etc. Some examples of laboratory animals include primates, rats, mice, rabbits, guinea pigs, etc.
[0102] As used herein, the phrase "altered RAS signaling" means any deviation in the activity of a RAS protein from that typically observed from wild-type RAS protein in a given tissue. Altered RAS signaling may include, for example, increased RAS signaling or decreased RAS signaling. Altered RAS signaling may be caused by one or more mutations in the RAS protein, such as the oncogenic mutations disclosed above. For example, certain RAS protein mutations may enable RAS protein to constitutively exist in its GTP-bound conformation, either by discouraging interaction of RAS protein with various GAP proteins or by disabling the GTPase activity of RAS protein.
[0103] As used herein, a RAS protein includes, but is not limited to any of the members of the RAS subfamily. Non-limiting examples of RAS subfamily members are set forth in Table 1 , below.
Table 1 : Example RAS Subfamily Members
Protein Synonym Accession
Number
Ras Subfamily NP_005334
H-Ras, isoform 1 NP_789765
H-Ras, isoform 2 H-RaslDX NP_002515
N-Ras NP_004976
K-Ras2B NP 203524
NP 006261
K-Ras2A NP 036382
NP 036351
R-Ras NP 002875
NP 056461
TC21 R-Ras2 NP 066361
NP_002877
M-Ras R-Ras3
NP 067006
RaplA Krev-1/Smgp21 NP_008843
NP 002921
Rapl B NP 054731
AAH35663
Rap2A NP 004156
NP 859053
Rap2B NP 005605
NP 653194
Rap2C NP 004666
NP 660156
Rit1 Roc1/RibB Rin/Roc2/RibA NP 060064
NP 853510
Rit2 Ges
NP 1 16307
NP 005393
Rem1
AAA36542
Rem2 R-Rad/Rem3 NP 002872
NP 065078
Rad Kir NP 060065
NP 057168
Gem Rheb2 NP 055125
NP 006468
NP 201572
Protein Synonym Accession
Number
Rhebl RhebU NP 996563
NP 076429
Rheb2 ARHI/Rhol Rig/GBTS1 NP_057647
Noey2 NP_079006
Di-Ras1 H-Ras2/H-RasP
Di-Ras2
E-Ras
Rerg
RalA, isoform 1
RalA, isoform 2 κΒ-Rasl
RalB KB-Ras2
NKIRasl DexRas/Ags1 Rhes/Tem2
NKIRas2 RasLI OA
RasD1
RasD2
RRP22
RasLI OB
RasL1 1A
RasL1 1 B
Ris/RasL12
[0104] In the present invention, a disease associated with altered RAS signaling may be a cancer, a neurological disorder, a metabolic disorder, an immunological disorder, an inflammatory disorder, and a developmental disorder. Preferably, the disease is autism, rasopathies, neurofibromatosis type 1 , Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, hereditary gingival
fibromatosis type 1 , Legius syndrome, Leopard syndrome, diabetic retinopathy, diabetes, hyperinsulinemia, chronic idiopathic urticarial, autoimmune lymphoproliferative syndrome, and capillary malformation-arteriovenous malformation.
[0105] Another embodiment of the present invention is a method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of the present invention.
[0106] Another embodiment of the present invention is a method for effecting cancer cell death comprising contacting a cancer cell with an effective amount of a compound of the present invention. In this embodiment, "contacting" means bringing the compound into close proximity to the cancer cell. This may be accomplished using conventional techniques of drug delivery to mammals or in the in vitro situation by, e.g., providing the compound to a culture media in which the cancer cell is located.
[0107] Suitable and preferred compounds are as disclosed herein. In this embodiment, effecting cancer cell death may be accomplished in cancer cells having various mutational backgrounds as disclosed above.
[0108] The methods of this embodiment, which may be carried out in vitro or in vivo, may be used to effect cancer cell death by, e.g., killing cancer cells, in cells of the types of cancer disclosed herein.
[0109] In one aspect of this embodiment, the cancer cell is a mammalian cancer cell. Preferably, the mammalian cancer cell is obtained from a mammal selected from a group consisting of humans, primates, farm animals, and domestic
animals and laboratory animals. More preferably, the mammalian cancer cell is a human cancer cell.
[0110] In the present invention, cancers include both solid and hemotologic cancers. Non-limiting examples of solid cancers include adrenocortical carcinoma, anal cancer, bladder cancer, bone cancer (such as osteosarcoma), brain cancer, breast cancer, carcinoid cancer, carcinoma, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, Ewing family of cancers, extracranial germ cell cancer, eye cancer, gallbladder cancer, gastric cancer, germ cell tumor, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, islet cell carcinoma, kidney cancer, large intestine cancer, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lung cancer, lymphoma, malignant mesothelioma, Merkel cell carcinoma, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian epithelial cancer, ovarian germ cell cancer, pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pituitary cancer, plasma cell neoplasm, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell cancer, transitional cell cancer of the renal pelvis and ureter, salivary gland cancer, Sezary syndrome, skin cancers (such as cutaneous t-cell lymphoma, Kaposi's sarcoma, mast cell tumor, and melanoma), small intestine cancer, soft tissue sarcoma, stomach cancer, testicular cancer, thymoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms' tumor.
[0111] Examples of hematologic cancers include, but are not limited to, leukemias, such as adult/childhood acute lymphoblastic leukemia, adult/childhood acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous
leukemia, and hairy cell leukemia, lymphomas, such as AIDS-related lymphoma, cutaneous T-cell lymphoma, adult/childhood Hodgkin lymphoma, mycosis fungoides, adult/childhood non-Hodgkin lymphoma, primary central nervous system lymphoma, Sezary syndrome, cutaneous T-cell lymphoma, and Waldenstrom macroglobulinemia, as well as other proliferative disorders such as chronic myeloproliferative disorders, Langerhans cell histiocytosis, multiple myeloma/plasma cell neoplasm, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms.
[0112] Preferably, the cancer is selected from a group consisting of pancreatic cancer, colorectal cancer, lung cancer, skin cancer, urinary bladder cancer, thyroid cancer, hematopoietic cancer, prostate cancer, breast cancer, liver cancer, soft tissue cancer, leukemia and bone cancer.
[0113] In a preferred aspect of this embodiment, the cancer is selected from a group consisting of pancreatic cancer, colorectal cancer, fibrosarcoma, breast cancer, lung cancer, skin cancer, leukemia and bone cancer.
[0114] Another embodiment of the present invention is a kit for treating or ameliorating the effects of a disease related to altered RAS signaling in a subject in need thereof, the kit comprising an effective amount of a compound or pharmaceutical composition of the present invention packaged together with instructions for its use.
[0115] Another embodiment of the present invention is a kit for treating or ameliorating the effects of a cancer in a subject in need thereof, the kit comprising an effective amount of a compound or pharmaceutical composition of the present invention, packaged together with instructions for its use.
[0116] The kits of the present invention may also include suitable storage containers, e.g. , ampules, vials, tubes, etc., for the compounds and compositions of the present invention and other reagents, e.g. , buffers, balanced salt solutions, etc., for use in administering the compounds and compositions to subjects. The compounds and compositions, including pharmaceutical compositions, of the present invention may be present in the kits in any convenient form, such as, e.g. , in a solution or in a powder form. The kits may further include a packaging container, optionally having one or more partitions for housing the compounds and pharmaceutical compositions and other optional reagents.
[0117] Another embodiment of the present invention is a composition comprising a compound of the present invention.
[0118] In one aspect of this embodiment, the composition is a research reagent. As used herein, a "research reagent" is any compound or composition used in the execution of investigational activities.
[0119] Another embodiment of the present invention is a compound that selectively binds a RAS protein at three or more sites, wherein when the compound is bound to the RAS protein, the compound binds to L56 of the RAS protein and blocks the binding of SOS to the RAS protein.
[0120] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0121] For recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9,
and for the range 6.0-7.0, the numbers 6.0, 6.1 , 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6,9, and 7.0 are explicitly contemplated.
EXAMPLES
[0122] The following examples are provided to further illustrate certain aspects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.
Example 1
Experimental Data
[0123] Software. Molecular docking was performed using GLIDE (Schrodinger, Inc). Modeling of proteins and ligands were performed using Molecular Operating Environment [MOE] (Chemical Computing Group).
[0124] In silico libraries. Libraries of commercially available compounds were compiled from the inventories of Asinex, Enamine, Chembridge, ChemDiv, IBS, Life, Maybridge and TimTec. A fragment subset of ~60,000 compounds of the unfiltered library was selected using the following filter criteria: LogP < 3, hydrogen bond acceptors <= 3, hydrogen bond donors <= 3, molecular weight < 300, aqueous solubility > 0.5 mM. Chemical descriptors were calculated using MOE (Chemical Computing Group).
[0125] Mic rosea le thermophoresis GTP-loaded KRASG12D was labeled at a surface-exposed cysteine residue using a NT-647-maleimide dye. Thermophoretic movement of the fluorescently labeled protein with the inhibitors was measured in capillaries across a 16-point dilution series using a Monolith NT.1 15 (Nanotemper Technologies).
[0126] General Procedures. All reactions were carried out under a nitrogen atmosphere under anhydrous conditions unless indicated otherwise. Anhydrous methylene chloride (CH2CI2) and tetrahydrofuran (THF) were purchased from Sigma- Aldrich. Reactions were magnetically stirred and monitored by thin layer chromatography on Merck pre-coated 0.25 mm silica plates containing a 254 nm fluorescence indicator. Flash chromatography was performed on a Teledyne combiflash companion automatic flash chromatography system. Preparative thin layer chromatography was performed on 1 mm SiliCycle prep plates. NMR spectra were obtained on a Bruker DPX 300 or 400 MHz spectrometer.
[0127] Abbreviations. EDIPA = diisopropylethyl amine, EtOAc = ethyl acetate, MeOH = methanol, DCE = 1 ,2-dichloroethane, Na2S04 = sodium sulfate, NaHC03 = sodium bicarbonate, Pd(PPh3)4
Tetrakis(triphenylphosphine)palladium(0), NH4CI = ammonium chloride, TFA = trifluoroacetic acid, HBTU = 0-(Benzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, HCI = hydrochloric acid, THF = tetrahydrofuran, K2CO3 = potassium carbonate. CH2CI2 = Dichloromethane, EtOH = ethanol.
[0128] Boc-amino Indole S1. To a solution of 1 H-indole-5-carbaldehyde (3.5 g, 24 mmol, 1 .0 equiv) in DMF (100 mL) at 0°C, sodium hydride (60% in mineral oil) (1.1 g, 28.8 mmol, 1 .2 equiv) was added in several portions over 5 minutes. The mixture was stirred for 45 minutes at 0°C before the sequential addition of 3-(Boc- amino)propyl bromide (8.00 g, 33.6 mmol, 1.4 equiv) and sodium iodide (3.6 g, 24 mmol, 1 .0 eq). The solution was warmed to 80°C and stirred for 48 hours. Upon completion, the reaction was diluted with saturated aqueous NaHCOs and extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried (Na2S04), concentrated, and the crude material was purified by flash column
chromatography (silica gel, hexanes/EtOAc, 1 : 1 ) (3.4 g, 47% yield). 1H NMR (400 MHz, CDCIs) δ 10.05 (s, 1 H), 8.18 (d, J = 1.5 Hz, 1 H), 7.81 (dd, J = 8.7, 1 .6 Hz, 1 H), 7.26 (d, J = 3.1 Hz, 1 H), 6.75-6.60 (m, 1 H), 4.54 (s, 1 H), 4.25 (t, J = 6.9 Hz, 2H), 3.17 (d, J = 7.2 Hz, 2H), 2.08 (p, J = 6.9 Hz, 2H), 1 .47 (s, 8H). 13C NMR (101 MHz, CDCI3) 192.44, 156.08, 139.19, 129.79, 129.34, 128.41 , 126.56, 121 .80, 109.80, 103.60, 44.05, 38.04, 30.63, 28.38. HRMS (m/z): [M+] calc'd for C17H22N2O3, 302.37, found 302.16.
[0129] Bromide 9 To a solution of S1 (FIG. 8) (1 .8 g, 5.95 mmol, 1 .0 equiv) in THF (120 mL) at -78°C, bromine (0.367 mL, 7.1 mmol, 1 .2 equiv) was added dropwise over 5 minutes. The resulting mixture was stirred at -78°C for 2 hours. Upon completion, the reaction contents were poured onto a solution of ice (~300 g), water (200 mL), ammonium hydroxide (1 mL, 12 M), sodium thiosultate pentahydrate (1 mL, saturated solution in water). The crude material was extracted with EtOAc (3 x 30 mL) and the combined organic extracts were then washed with water (100 mL) and brine (100 mL), dried (Na2S04), filtered, and concentrated. The crude material was purified by flash column chromatography (silica gel, hexanes/EtOAc, 1 :1 ) to afford 9 (1.2 g, 53% yield). 9:1 H NMR (400 MHz, CDCI3) δ 10.09 (s, 1 H), 8.12 (d, J = 1 .5 Hz, 1 H), 7.86 (dd, J = 8.7, 1 .5 Hz, 1 H), 7.43 (d, J = 8.6 Hz, 1 H), 7.30 (s, 1 H), 4.57 (s, 1 H), 4.23 (t, J = 6.9 Hz, 2H), 3.18 (d, J = 6.8 Hz, 2H), 2.08 (q, J = 6.7 Hz, 2H), 1 .47 (s, 9H). 13C NMR (101 MHz, CDCI3) 191 .19, 155.31 , 137.89, 128.98, 127.87, 126.53, 124.05, 121 .63, 109.40, 91 .20, 78.67, 76.65, 76.33, 76.01 , 43.54, 37.09, 29.82, 27.57, 27.54. HRMS (m/z): [M+] calc'd for Ci7H2i BrN203, 381 .26, found 380.07. (FIG. 6)
[0130] Benzyl Alcohol 10 To a solution of 9 (1 .60 g, 4.20 mmol, 1 .0 equiv) in dioxane (10 mL), 3-(hydroxylmethyl)phenylboronic acid (0.640 g, 4.20 mmol, 1 .0 eq),
Pd(PPh3)4 (0.250 g, 0.195 mmol, 0.05 equiv), and a solution of K2C03 (1 .10 g, 8.40 mmol, 2.0 equiv) in water were added sequentially. The resulting mixture was heated to 80°C and stirred for 48 hours. Upon completion, the reaction was diluted with saturated aqueous NaHCOs and extracted with EtOAc (3 x 10 mL). The combined organic extracts were then washed with water (20 mL) and brine (20 mL), dried (Na2S04), filtered, and concentrated. The crude material was purified by flash column chromatography (silica gel, hexanes/EtOAc, 1 : 1 ) to afford 10 (1 .4 g, 85% yield). 1H NMR (400 MHz, CDCI3) δ 10.1 1 (s, 1 H), 8.41 (s, 1 H), 7.85 (dd, J = 1.1 Hz, 8.6 Hz, 1 H), 7.65 (m, 2 H), 7.47 (m, 3 H), 7.37 (d, J = 7.6 Hz, 1 H), 7.29 (s, 1 H), 4.70 (s, 3 H), 4.29 (t, J = 7.0 Hz, 2 H), 3.21 (m, 2 H), 2.12 (t, J = 6.8 Hz, 2 H), 1 .46 (s, 9 H). (FIG. 6)
[0131] Aldehyde 12 To a solution of 10 (0.250 g, 0.61 mmol, 1 .0 equiv) in CH2CI2 (3 mL) at 0°C was added triethylamine (0.2 mL, 1 .22 mmol, 2.0 equiv) and methanesulfonyl chloride (0.1 mL, 1 .22 mmol, 2.0 equiv). The reaction was allowed to warm to 25°C and stirred for 2 hours. Upon completion, the reaction was quenched with saturated aqueous NH4CI and extracted with CH2CI2 (3 x 5 mL). The combined organic extracts were then washed with water (20 mL) and brine (20 mL), dried (Na2S04), filtered, and concentrated. A portion of the crude material 11 (0.130 g, 0.27 mmol, 1 .0 equiv) was taken forward without further purification, and dissolved in DMF (2 mL). Indole L56 fragment (0.070 g, 0.27 mmol, 1 .0 equiv, prepared according to a published procedure from Sun et al. Ang. Chem. Int. Ed. 2012, 51 , 6140), was added as a solution in DMF (1 mL). Triethylamine (0.1 1 mL, 0.81 mmol, 3.0 equiv) and sodium iodide (0.120 g, 0.8 mmol, 3.0 equiv) were added sequentially, and the solution was heated at 80°C overnight. Upon completion, the reaction was quenched with saturated aqueous NH4CI and extracted with CH2CI2 (3 x
5 mL). The combined organic extracts were then washed with water (20 mL) and brine (20 mL), dried (Na2S04), filtered, and concentrated. The crude material was purified by flash column chromatography (silica gel, 10% MeOH in CH2CI2) to afford 12 (0.140 g, 80% yield). 12: 1 H NMR (400 MHz, CDCI3) δ 9.69 (s, 1 H), 8.22 (s, 1 H), 7.76 (m. 2 H), 7.58-7.53 (m, 3 H), 7.43-7.29 (m, 5 H), 7.17 (s, 1 H), 7.07 (t, J = 7.1 Hz, 1 H), 6.92 (t, J = 7.2 Hz, 1 H), 6.74 (m, 2 H), 4.45 (s, 2 H), 4.28 (m, 4 H), 3.08 (m, 2 H), (2.01 (m, 3 H), 1 .45 (s, 9 H). (FIG. 6)
[0132] 1-(2,6-dichlorobenzyl)piperazine. To a solution of piperazine (1 12 mmol, 6.0 eq) in THF (180 mL) at 0°C, a solution of 2,6-dichlorobenzyl bromide (4.5 g, 18.8 mmol) in THF (20 mL) was added dropwise over 10 minutes. The resulting mixture was slowly allowed to warm to room temperature and stirred for 24 hours. Upon completion the THF was removed and the crude material was re-suspended in CH2CI2 and water, and extracted 2 additional times with CH2CI2. The combined organic layers were dried (Na2S04), concentrated, and the crude material was purified by flash column chromatography (20% MeOH in CH2CI2) to afford 1 -(2,6- dichlorobenzyl)piperazine (2.3 g, 50% yield). 1 H NMR (400 MHz, Methanol-d4) δ 7.62 -7.30 (m, 2H), 7.23 (dd, J = 8.7, 7.4 Hz, 1 H), 3.74 (s, 2H), 2.92-2.69 (m, 4H), 2.56 (t, J = 4.9 Hz, 4H). 13C NMR (101 MHz, MeOD) 136.76, 133.67, 129.18, 128.24, 56.55, 53.41 , 44.95. HRMS (m/z): [M+] calc'd for Cn H14CI2N2, 245.15, found 245.06.
[0133] Piperazine 13 To a solution of 12 (0.1 10 g, 0.17 mmol, 1 .0 equiv) in DCE (2 mL), 1 -(2,6-dichlorobenzyl)piperazine (0.125 g, 0.50 mmol, 3.0 equiv) and zinc chloride (5.0 mg, 0.034 mmol, 0.2 equiv) were added sequentially. The resulting mixture was stirred at 60°C for 2 hours before the addition of a solution of sodium cyanoborohydride (20.0 mg, 0.34 mmol, 2.0 equiv) in methanol (0.5 mL). The resulting mixture was stirred for an additional 2 hours at 60°C. Upon completion the
reaction was concentrated and purified directly by flash column chromatography (silica gel, 10% MeOH in CH2CI2) to afford 13 (0.090 g, 60% yield). 13: 1 H NMR (400 MHz, MeOD) δ 7.73 (s, 1 H), 7.52 (s, 1 H), 7.47-7.07 (m, 14 H), 6.96 (m, 1 H), 6.71 (dd, J = 2.1 Hz, 8.7 Hz, 1 H), 6.66 (d, J = 1 .7 Hz, 1 H), 4.42 (s, 2 H), 4.27 (s, 2 H), 4.21 (s, 2 H), 3.73 (s, 2 H), 2.60 (br s, 4 H), 2.47 (br s, 4 H), 1 .99 (t, J = 6.8 Hz, 2 H), 1 .42 (s, 9 H). (FIG. 6)
[0134] 04SBT04 To a solution of 13 (0.100 g, 0.12 mmol, 1 .0 equiv) in dioxane (2 ml_), excess HCI (0.1 ml_, 4.0 M in dioxane) was added and the resulting solution was stirred for 24 hours. Upon completion, the dioxane was removed and the crude material was re-suspended in methanol and an excess of K2CO3 was added (~100 mg). The slurry was stirred at room temperature for 1 hour to ensure basification. K2CO3 was filtered off, and the solution was concentrated and purified by flash column chromatography (silica gel, 20% MeOH in CH2CI2) to afford S2. A portion of this material (0.025 g, 0.032 mmol, 1 .0 equiv) was added to a pre-stirred (0°C, 30 minutes) solution of HBTU (0.014 g, 0.05 mmol, 1 .5 equiv), 4-amino-1 -(tert- butoxycarbonyl)piperidine-4-carboxylic acid (0.012 g, 0.05 mmol, 1 .5 equiv) and EDIPA (0.01 ml_, 0.05 mmol, 2.0 equiv)) in DMF (2 ml_) and stirred for an additional 6 h at 25°C. Upon completion, the reaction was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (3 x 2 ml_). The combined organic layers were washed with water (10 ml_), brine (10 ml_), dried (Na2SO4), concentrated, and purified by flash column chromatography (silica gel, 20% MeOH in CH2CI2) to afford S3. A portion of this slightly impure material (0.020 g) was dissolved in dioxane (1 ml_) and HCI (0.1 ml_, 4.0 M in dioxane) was added. The resulting mixture was stirred for 6 h at 25°C. After removal of dioxane, the residue was re-suspended in MeOH and excess K2CO3 (100 mg) was added. After stirring for 1 h, K2CO3 was
filtered off, and the solution was concentrated and purified by preparative TLC (20% MeOH in DCM) to afford 04SBT04 (0.010 g). 04SBT04: 1 H NMR (400 MHz, MeOD) δ 7.76 (s, 1 H), 7.58 (s, 1 H), 7.52-7.17 (m, 13 H), 7.08 (t, J = 7.2 Hz, 1 H), 6.92 (t, J = 7.2 Hz, 1 H), 6.72 (m, 2 H), 4.46 (m, 3 H), 4.29 (m, 5 H), 3.77 (m, 3 H), 2.62 (br s, 4 H), 2.45 (br s, 4 H), 2.1 1 (m, 2 H), 1 .48 (m, 1 H). (FIGs. 6 and 8)
[0135] Acid 15 To a solution of 2-(5-nitro-1 H-indol-3-yl)acetic acid (14, 0.200 g, 0.92 mmol, 1 .0 equiv) in MeOH (5 mL), excess pTsOH (0.800 g, 4.5 mmol, 5.0 equiv) was added. The solution was heated under reflux for three days, quenched with saturated aqueous NaHCO3, poured into water and extracted with EtOAc (3 x 5 mL). The combined organic extracts were then washed with water (10 mL) and brine (10 mL), dried (Na2SO4), filtered, and concentrated to afford pure methyl ester S4 in quantitative yield. The crude material was reduced under hydrogen atmosphere in the presence of catalytic Pd/C in EtOAc overnight to afford S5. This material was advanced without further purification and the aryl amino group was Boc-protected with excess Boc2O and NaHCO3 in THF for 2 h at 25°C to afford S6. Crude S6 was subsequently subjected to excess KOH in THF/water overnight in order to saponify the ester to the corresponding carboxylic acid 15 (0.180 g, 67% yield from 14). 15: 1 H NMR (400 MHz, CDCI3) δ 8.34 (s, 1 H), 7.61 (s, 1 H), 7.18 (m, 2 H), 6.59 (s, 1 H),
3.75 (s, 2 H), 1 .56 (s, 9 H). (FIG. 7A and FIG. 8)
[0136] Amino-indole 18. Intermediate 15 (0.250 g, 0.86 mmol) was advanced towards 17 using the identical conditions previously described by Sun et al. 17 could be subsequently deprotected using excess HCI (4.0 M in dioxane) overnight to afford 18 (0.100 g, 38% yield from 15). 18: 1H NMR (400 MHz, CDCI3) δ 8.08 (d, J = 2.6 Hz, 1 H), 7.91 (dd, J = 2.6 Hz, 9.0 Hz, 1 H), 7.23 (m, 2 H), 7.08 (d, J = 1.8 Hz, 1 H),
6.76 (m, 2 H), 3.85 (s, 2 H). (FIG. 7A)
[0137] Vinyl amide 19 To a solution of 18 (0.012 g, 0.04 mmol, 1 .0 equiv) in
THF (1 mL) was added excess triethylamine (0.01 mL) and acryloyl chloride (0.01 mL, 0.1 mmol, 2.5 equiv) at 0°C. After stirring at 0°C for 1 hour, the reaction contents were quenched with saturated aqueous NH4CI, poured into water and extracted with CH2CI2 (3 x 5 mL). The combined organic extracts were then washed with water (10 mL) and brine (10 mL), dried (Na2S04), filtered, and concentrated. The resultant crude, yellow oil was purified by preparative TLC (10% MeOH in CH2CI2) to afford S7 (0.010 g, 69% yield). This material was then reduced with catalytic Fe/HCI in a mixture of EtOH/water to afford 19 in quantitative yield. 19: 1 H NMR (400 MHz, MeOD) δ 7.69 (s, 1 H), 7.37 (m, 2 H), 7.27 (d, J = 8.5 Hz, 1 H), 7.23 (s, 1 H), 6.85 (d, J = 1 .7 Hz, 1 H), 6.71 (dd, J = 2.1 Hz, 8.5 Hz, 1 H), 6.44 (dd, J = 1 10.0 Hz, 17.0 Hz, 1 H), 6.34 (dd, J = 1.7 Hz, 10.0 Hz, 1 H), 5.73 (dd, J = 1 .7 Hz, 17 Hz, 1 H), 4.32 (s, 2 H). (FIG. 7B and FIG. 8)
[0138] Chloroacetamide 20 To a solution of 18 (0.012 g, 0.04 mmol, 1 .0 equiv) in THF (1 mL) was added excess triethylamine (0.01 mL) and chloroacetyl chloride (0.01 mL, 0.1 mmol, 2.5 equiv) at 0°C. After stirring at 0°C for 1 hour, the reaction contents were quenched with saturated aqueous NH4CI, poured into water and extracted with CH2CI2 (3 x 5 mL). The combined organic extracts were then washed with water (10 mL), brine (10 mL), dried (Na2SO4), filtered, and concentrated. The resultant crude, yellow oil was purified by preparative TLC (10% MeOH in CH2CI2) to afford S8 (0.009 g, 57% yield). This material was then reduced under hydrogen atmosphere in the presence of catalytic Pd/C in EtOAc overnight to afford 20 in quantitative yield. 20: 1H NMR (400 MHz, MeOD) δ 7.74 (dd, J = 1 .5 Hz, 8.5 Hz, 1 H), 7.42-7.27 (m, 4 H), 7.18 (d, J = 2.5 Hz, 1 H), 6.83 (d, J = 8.5 Hz, 1 H), 6.52 (m, 1 H), 4.21 (s, 2 H), 3.85 (s, 2 H). (FIG. 7B and FIG. 8)
[0139] Aldehyde 21. To a solution of 18 in THF excess triethylamine and 2- iodoethanol are added at 0°C. After stirring at 0°C, the reaction contents are quenched with saturated aqueous NH4CI, poured into water and extracted with CH2CI2. The combined organic extracts are then washed with water and brine, dried (Na2S04), filtered, and concentrated. The resultant crude, product is purified by preparative TLC. Oxidation of the primary alcohol to an aldehyde is accomplished by, for example, Swern oxidation. This material is then reduced under hydrogen atmosphere in the presence of catalytic Pd/C in EtOAc overnight to afford 21 (FIG. 7B).
Example 2
[0140] Targeting RAS PPIs initially relied upon analysis of the co-crystal structures of HRAS with ΡΙ3Κγ (PDB: 1 HE8), with the RAF RAS-binding domain (RBD, PDB: 3KUD), and with RALGDS (PDB: 1 LFD) in order to gain insights regarding conserved effector regions. A particularly persistent site of RAS-effector interaction sits along a short stretch of amino acids within the switch I region (red), highlighted in FIG. 3A to display the apparent overlap with the D38 site (green) shown in FIG. 3B. Subsequent analysis of the KRASG12D (PDB: 4DSN) structure revealed a shallow pocket directly adjacent to the D38 site in between the switch I and switch II (blue) regions, denoted as the A59 site (purple). These observations informed a multivalent ligand approach targeting the D38 and A59 sites based on in silico library design and fragment screening, resulting in 31 MEW44, a novel inhibitor of KRASG12D.
[0141] Design of Novel Three-Site Compounds. Further analysis of the proposed binding mode of 31 MEW44 with KRASG12D divulged an additional shallow
pocket adjacent to the trifluoromethylphenyl ring near L56 (FIG. 4A). This region has previously been the focus of several fragment-based screening efforts described earlier in this section, as it is the site of SOS-mediated nucleotide exchange towards activated GTP-bound KRAS (Sun et al., Maurer et al.). As such, it is a relevant effector region to GDP-bound RAS, while efforts have extensively focused on the GTP-bound conformation to this point. The possibility of extending into this pocket through derivation of 31 MEW44 at the 3-position of the aryl ring neighboring the L56 site would potentially generate compounds targeting three distinct sites to infer greater inhibitory efficiency and binding affinity for KRASG12D .
[0142] Towards accomplishing this goal, an in silico screen of 60,000 commercially available fragments constrained to the L56 residue was conducted. The top-scoring fragment is pictured in FIG. 4B. While this particular substrate is not readily accessible through synthetic transformations that would facilitate incorporation into an analog of 31 MEW44, it shared an obvious resemblance to the synthetically feasible benzimidazole/indole-based scaffold (L56-fragment). This scaffold was the basis of inhibitors developed by Sun et al., which targeted an identical region of GDP-bound RAS. Virtual docking of a fully elaborated 3-site compound (L56 3-site) returned the anticipated docking pose (FIG. 5A) with the newly introduced fragment making multiple contacts at the L56 site, namely electrostatic interactions with Q37 and T74 (FIG. 5B). Intriguingly, the docking score of this novel 3-site compound was significantly higher than that of 31 MEW44 (docking score = -9.3), further propagating the notion that we could achieve augmented inhibition by simultaneously targeting an alternate site.
[0143] Synthesis of the target compound was accomplished as outlined in Scheme 1 (FIG. 6). Alterations to the original 31 MEW44 route, specifically the
exchange of the trifluoromethyl ether aryl boronic acid to a benzyl alcohol analog, afforded the opportunity for incorporation of the L56-fragment through nucleophilic displacement of an appropriately derived electrophile, in this case benzyl mesylate 11. While initial transformations required some optimization, no additional modifications to the original route were necessary, effectively delivering 04SBT04 for biochemical evaluation.
[0144] An assay of the dissociation constant (KD) of 04SBT04 to GTP-bound RAS will ascertain potency relative to 31 MEW44 structure shown below:
Example 3
[0145] Evaluating Covalent Inhibition at L56 Site. While analyzing the L56 site in pursuit of a novel 3-site compound, the presence of several potentially nucleophilic residues lining this pocket was noted, namely K5. There was a possibility of developing irreversible inhibitors at L56 and assaying the
pharmacological consequences of covalently modifying RAS at this site. This approach hinged upon the ability to introduce adequately positioned electrophihc moieties into a scaffold already possessing appreciable affinity for the targeted pocket. Since the L56-fragment had been separately validated by Sun et al. and our independent virtual screens, it was seen as an appropriate scaffold for evaluating the hypothesis. Given the observed docking pose of this fragment, it was reasoned that derivation of the indole ring with electrophihc moieties gave the greatest likelihood of effectively engaging a nucleophilic residue. These electrophile-derived fragments could be incorporated into analogs of 04SBT04, potentially generating highly selective covalent inhibitors.
[0146] The synthetic routes towards these electrophihc fragments are depicted in Scheme 2 (FIG. 7), relying on amino-substituted indole analog 18. After modifications of the synthetic route towards L56-fragment, the aryl amine analog with electrophihc warheads could effectively be derived to arrive at the target probes for assessing irreversible inhibition. Mass spectroscopy experiments capable of discerning covalent modification of RAS will be conducted.
[0147] In order to effectively capture the vast landscape of challenging, yet disease-modifying, therapeutic targets, innovative approaches to drug discovery are paramount. Work in this field suggests that rational, structure-guided design of multivalent ligands capable of mitigating protein-protein interactions is a viable option. The current strategy resulted in the generation of pan-RAS inhibitors demonstrating intriguing activity in biochemical, in vitro, and in vivo assays.
Documents
AHEARN, I. M.; Haigis, K.; Bar-Sagi, D.; Philips, M. R. Nat. Rev. Mol. Cell Bio. 2012, 13, 39.
BAKER, N. M.; Der, C. J. Nature. 2013, 497, 577.
BERGE, S.M. et al. "Pharmaceutical salts." J. Pharm. Sci. 1977, 66, 1 -19.
BLOCK, C; et al. Nat. Struct. Bio. 1996, 3, 244.
COX, A. D.; Fesik, S. W.; Kimmelman, A. C; Luo, J.; Der, C. J. Nat. Rev. Drug Discov. 2014, 13, 828.
DOWNWARD, J. Nat. Rev. Cancer. 2003, 3, 1 1 .
HALL, B. E.; Bar-Sagi, D.; Nassar, N. PNAS. 2002, 99, 12138.
HOPKINS, A. L; Groom, C. R. Nat. Rev. Drug Discov. 2002, 1 , 727.
HUANG, L; et al. Nat. Struct. Bio. 1998, 5, 422.
JOHN, J.; et al. Biochemistry. 1990, 29, 6058.
MAURER, T.; et al. PNAS. 2012, 109, 5299.
MESA, R. A. Expert Rev. Anticancer Ther. 2006, 6, 313.
NERO, T. L. Nat. Rev. Cancer. 2014, 14, 248.
OSTREM, J. M.; Peters, U.; Sos, M. L; Wells, J. A.; Shoukat, K. M. Nature. 2013, 504, 548.
PACOLD, M. E.; et al. Cell. 2000, 103, 931 .
PARIKH, C. et al. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res. 2007, 67(15), 7139-46.
PATGIRI, A.; Yadav, K. K.; Bar-Sagi, D. Nat. Chem. Bio. 201 1 , 7, 585.
PRIOR, I. A.; Lewis, P. D.; Mattos, C. Cancer Res. 2012, 72, 2457.
RAVOET, C; Mineur, P.; Robin, V.; Debusscher, L; Bosly, A.; Andre, M.; Housni, H.
E.; Soree, A.; Bron, D.; Martiat, P. Ann. Hematol. 2008, 87, 881 .
SHIMA, F.; et al. PNAS. 2013, 20, 5299.
SUN, Q.; Burke, J. P.; Phan, J.; Burns, M. C; Olejniczak, E. T.; Waterson, A. G.; Lee, T.; Rossanese, 0. W.; Fesik, S. W. Ang. Chem. Int. Ed. 2012, 51 , 6140.
VALENCIA, Alfonso, et al. "The ras protein family: evolutionary tree and role of conserved amino acids." Biochemistry. 1991 , 30(19), 4637-4648.
VASSILEV, L. T. Science. 2004, 303, 844.
ZIMMERMANN, G.; Papke, B.; Ismail, S.; Vartak, N.; Chandra, A.; Hoffman, M.; Hahn, S. A.; Triola, G.; Wittinghofer, A.; Bastiaens, P. I. H.; Waldmann, H. Nature. 2013, 497, 638.
[0148] All patents, patent applications, and publications cited above are incorporated herein by reference in their entirety as if recited in full herein.
[0149] The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.
Claims
What is claimed is:
1 . A compound that selectively binds a RAS protein at three or more sites, which compound selectively binds to a first site on the RAS protein that comprises at least one amino acid near L56.
2. The compound according to claim 1 , which selectively binds to a second site on the RAS protein that comprises at least one amino acid from the switch 1 region (near D38).
3. The compound according to claim 2, which selectively binds to a third site on the RAS protein that comprises at least one amino acid located between the switch 1 and switch 2 regions (near A59).
4. The compound according to claim 1 , wherein the RAS protein is an isoform selected from a group consisting of HRAS, KRAS, NRAS, and combinations thereof.
5. The compound according to claim 1 , wherein the RAS protein is an oncogenic mutant.
6. The compound according to claim 5, wherein the RAS protein is an oncogenic mutant selected from a group consisting of HRASG12D KRASG12D NRAS 061 K N RASG13V AND N RASGI 3D
7. The compound according to claim 1 that selectively binds to at least one amino acid near D38 and at least one amino acid near A59 in the RAS protein.
8. The compound according to claim 7 that comprises a region A that binds to at least one amino acid near D38 on the RAS protein and comprises a heterocycle with at least one ring nitrogen.
9. The compound according to claim 8, wherein the A region of the compound comprises a fragment having formula (I):
wherein ring A is a heterocycle with at least one ring nitrogen, and R-i is selected from a group consisting of no atom, amine, and Ci-4 aliphatic.
10. The compound according to claim 9, wherein the A region of the compound is selected from a group consisting of:
1 1 . The compound according to claim 7 that comprises a region B that binds to at least one amino acid near A59 on the RAS protein and comprises an indole.
The compound according to claim 1 1 , wherein the B region of the compound prises a structure of formula (III):
wherein
R3 is selected from a group consisting of heterocycle, aryl, and amine, which heterocycle, aryl, and amine may be optionally substituted with a group selected from halide, Ci-4 aliphatic, and combinations thereof; and
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with halide.
13. The compound according to claim 1 1 , wherein the B region of the compound is selected from a group consisting of
wherein
R2 and R5 are independently selected from a group consisting of no atom, aryl, and Ci-4 aliphatic; and
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with halide.
14. The compound according to claim 7, that comprises a region C, which region comprises a structure of formula (IV):
wherein R6 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci-4alkyl, and combinations thereof.
15. The compound according to claim 1 that comprises a region D that binds to at least one amino acid near L56 on the RAS protein comprising a structure of formula (VII):
wherein R 2, R13, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH, 0, and S, and wherein E is an electrophile.
16. The compound according to claim 15, wherein E is selected from a group consisting of
wherein:
Y is selected from a group consisting of CI, Br, F, I, and N2;
Z is selected from a group consisting of 0 and NH; and
R-16 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with a group consisting of halide, ether, Ci-4alkyl, and combinations thereof; and
p is 1 , 2, or 3.
wherein:
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci-4alkyl, and combinations thereof;
R9 is selected from a group consisting of no atom, H, and aryl optionally substituted with a group consisting of ether, halide, and combinations thereof;
Ri2, Ri 3, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and
ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
18. The compound according to claim 1 , wherein the compound has a structure of formula (VI):
wherein:
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 and R-n are independently selected from a group consisting of no atom, H, alkyi, and aryl, wherein the alkyi is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, d- 4alkyl, and combinations thereof;
R-io is selected from a group consisting of no atom, H, halide, and Ci-4 aliphatic;
Ri2, Ri3, Ri4, and Ri5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
19. The compound according to claim 1 , wherein the compound is selected from a group consisting of
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
20. A compound having the structure of formula (V):
wherein:
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 is selected from a group consisting of no atom, H, alkyl, and aryl, wherein the alkyl is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, Ci-4alkyl, and combinations thereof;
R9 is selected from a group consisting of no atom, H, and aryl optionally substituted with a group consisting of ether, halide, and combinations thereof;
Ri2, Ri 3, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and
ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
21 A compound having the structure of formula (VI):
wherein:
R4 is selected from a group consisting of no atom, H, aryl, halide, Ci-4 aliphatic, and -0-Ci-4 aliphatic, wherein the Ci-4 aliphatic is optionally substituted with one or more halide;
R8 and R-n are independently selected from a group consisting of no atom, H, alkyi, and aryl, wherein the alkyi is optionally substituted with a group consisting of halide, ether, and combinations thereof, and the aryl is optionally substituted with one or more groups consisting of halide, ether, d- 4alkyl, and combinations thereof;
R-io is selected from a group consisting of no atom, H, halide, and Ci-4 aliphatic;
Ri2, Ri3, Ri4, and Ri5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile;
m and n are independently selected from integers between 0-5; and ring A is a heterocycle with at least 1 ring nitrogen and optionally substituted with Ci-4alkyl or a halide,
stalline form, hydrate, or pharmaceutically acceptable salt thereof.
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
23. A compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof. 24. A compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
A compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof. 26. A compound having the structure:
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
wherein R 2, R13, Ri4, and R 5 are independently selected from a group consisting of H and -X-E, wherein X is selected from a group consisting of a bond, NH and 0, and wherein E is an electrophile,
or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof,
with the provisio that at least one of R 2, R13, Ri4, and R 5 are not H.
28. A compound selected from a group consisting of
and crystalline forms, hydrates, or pharmaceutically acceptable salts thereof.
29. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 , 20-22 and 27-28.
30. A method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a compound according to any one of claims 1 , 20-22 and 27-28.
31 . The method according to claim 30, wherein the disease is selected from a group consisting of a cancer, a neurological disorder, a metabolic disorder, an immunological disorder, an inflammatory disorder, and a developmental disorder.
32. The method according to claim 31 , wherein the disease is selected from a group consisting of autism, rasopathies, neurofibromatosis type 1 , Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, hereditary gingival fibromatosis type 1 , Legius syndrome, Leopard syndrome, diabetic retinopathy, diabetes, hyperinsulinemia, chronic idiopathic urticarial, autoimmune lymphoproliferative syndrome, and capillary malformation-arteriovenous malformation.
33. The method according to claim 31 , wherein the cancer is selected from a group consisting of pancreatic cancer, colorectal cancer, lung cancer, skin cancer, urinary bladder cancer, thyroid cancer, hematopoietic cancer, prostate cancer, breast cancer, liver cancer, soft tissue cancer, leukemia and bone cancer.
34. The method according to claim 31 , wherein the cancer is selected from a group consisting of pancreatic cancer, colorectal cancer, fibrosarcoma, breast cancer, lung cancer, skin cancer, leukemia and bone cancer.
35. The method according to claim 30, wherein the subject is a mammal.
36. The method according to claim 35, wherein the mammal is selected from a group consisting of humans, primates, farm animals, domestic animals and laboratory animals.
37. The method according to claim 35, wherein the mammal is a human.
38. A method for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject comprising administering to the subject an effective amount of a pharmaceutical composition according to claim 29.
39. A method for effecting cancer cell death comprising contacting a cancer cell with an effective amount of a compound according to any one of claims 1 , 20-22 and 27-28.
40. A kit for treating or ameliorating the effects of a disease related to altered RAS signaling in a subject in need thereof, the kit comprising an effective amount of a compound according to any one of claims 1 , 20-22 and 27-28, packaged together with instructions for its use.
41 . A kit for treating or ameliorating the effects of a disease related to altered RAS signaling in a subject in need thereof, the kit comprising an effective amount of a pharmaceutical composition according to claim 29, packaged together with instructions for its use.
42. A kit for treating or ameliorating the effects of a cancer in a subject in need thereof, the kit comprising an effective amount of a compound according to any one of claims 1 , 20-22 and 27-28, packaged together with instructions for its use.
43. A kit for treating or ameliorating the effects of a cancer in a subject in need thereof, the kit comprising an effective amount of a pharmaceutical composition according to claim 29, packaged together with instructions for its use.
44. A composition comprising a compound according to any one of claims 1 , 20- 22 and 27-28.
45. The composition according to claim 44, which is a research reagent.
46. A compound that selectively binds a RAS protein at three or more sites, wherein when the compound is bound to the RAS protein, the compound binds to L56 of the RAS protein and blocks the binding of SOS to the RAS protein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562155352P | 2015-04-30 | 2015-04-30 | |
US62/155,352 | 2015-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016176338A1 true WO2016176338A1 (en) | 2016-11-03 |
Family
ID=57199835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/029582 WO2016176338A1 (en) | 2015-04-30 | 2016-04-27 | Small molecule ras ligands |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016176338A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130231346A1 (en) * | 2010-11-17 | 2013-09-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
WO2013155223A1 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
US20130317047A1 (en) * | 1999-08-27 | 2013-11-28 | Aventis Pharma Deutschland Gmbh | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
EP2671575A1 (en) * | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
US20140024123A1 (en) * | 2011-02-07 | 2014-01-23 | National University Corporation Kobe University | Aqueous Solution Containing Partial Ras Polypeptide and Method for Screening Inhibitor of Ras Function |
-
2016
- 2016-04-27 WO PCT/US2016/029582 patent/WO2016176338A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130317047A1 (en) * | 1999-08-27 | 2013-11-28 | Aventis Pharma Deutschland Gmbh | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
US20130231346A1 (en) * | 2010-11-17 | 2013-09-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
US20140024123A1 (en) * | 2011-02-07 | 2014-01-23 | National University Corporation Kobe University | Aqueous Solution Containing Partial Ras Polypeptide and Method for Screening Inhibitor of Ras Function |
WO2013155223A1 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
EP2671575A1 (en) * | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11136297B2 (en) | Compositions and methods for treating cancer | |
CN106488910B (en) | Inhibitors of KRAS G12C | |
KR102210316B1 (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
JP4623962B2 (en) | Protein kinases and phosphatase inhibitors, methods of designing them, and methods of using them | |
EP3148981A2 (en) | Multivalent ras binding compounds | |
ES2536730T3 (en) | 3,4-Dihydro-2H-pyrrolo [1,2-a] pyrazin-1-one derivatives | |
JP2020513036A (en) | Compounds involved in cooperative binding and uses thereof | |
US20210403415A1 (en) | Compounds and methods to attenuate tumor progression and metastasis | |
CA3215949A1 (en) | Oxazepine compounds and uses thereof in the treatment of cancer | |
BR112020000564A2 (en) | new heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and / or 2 (hdac1-2) | |
CN116528868A (en) | Tricyclic KRAS G12C inhibitors | |
JP2018508563A (en) | USP7 inhibitor compounds and methods of use | |
WO2016176338A1 (en) | Small molecule ras ligands | |
CN115380033A (en) | SETD2 inhibitors and related methods and uses, including combination therapies | |
WO2020221006A1 (en) | Bet inhibitor, and preparation method and use thereof | |
WO2022079290A2 (en) | Cullin ring ubiquitin ligase compounds and uses thereof | |
AU2021359129A9 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
US11896589B2 (en) | Diazinyl amino acridines and medical uses thereof | |
US20140378516A1 (en) | Compositions, methods of use, and methods of treatment | |
WO2023059597A1 (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
EP2908813A1 (en) | Compounds for treating rac-gtpase mediated disorder | |
US20210363105A1 (en) | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof | |
Li et al. | Discovery of MD-224 as a First-in-Class, Highly Potent and Efficacious PROTAC MDM2 Degrader Capable of Achieving Complete and Durable Tumor Regression | |
Cervi et al. | Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors | |
Tosso | Design and synthesis of small molecule disruptors of EWS-FLI1 in Ewing's sarcoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16787074 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16787074 Country of ref document: EP Kind code of ref document: A1 |